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ABSTRACT 
Endothelial cells (ECs) are part of almost every human organ, and disturbance in their 
function can cause several human diseases such as pulmonary arterial hypertension. We 
sought to develop an in vitro model to derive ECs from human induced pluripotent stem 
cells (hiPSCs) in an effort to develop future regenerative therapies or disease models. By 
stimulating signaling pathways gleaned from prior studies of the early embryonic 
development of endothelial cells and their precursor germlayer, mesoderm, hiPSCs were 
differentiated in vitro using a media containing 10ng/ml of Activin, FGF2, VEGF and 
BMP4 to induce mesoderm over 4 days, followed by VEGF and FGF2 to subsequently 
specify ECs. By day 12, putative endothelial cells identified by the co-expression of 
CD31, CD144 and KDR, emerged and could be sorted and re-plated in endothelial 
maintenance media for expansion over several passages. Time series characterization of 
mRNA and protein gene expression indicates that to form endothelial cells, hiPSCs 
developmentally differentiate first into a posterior primitive streak-like stage (indicated 
by high T and low FOXA2 expression), then into a heterogeneous population of 
mesodermal subsets (day 4). Subsequently, lateral plate mesoderm cells predominate over 
intermediate or paraxial mesoderm. To understand the role of BMP4 in this process, each 
iv 
factor was withheld from various stages of the protocol. Results indicate that before day 
4, BMP4 alone is necessary and sufficient to direct cells through posterior primitive 
streak into mesodermal progenitors that upon subsequent VEGF/FGF2 exposure can give 
rise to CD31+CD144+KDR+ endothelial-like cells.  In contrast, BMP4 is dispensable after 
day4, whereas VEGF and FGF2 are dispensable in the first 4 days of the protocol.  To 
develop a disease model hiPSCs from patients with BMPR2 mutations associated with 
pulmonary hypertension were generated by reprogramming their archived fibroblasts. By 
differentiating these patient-specific iPSCs into mesodermal progenitors and ECs using 
our protocol, preliminary results indicate that the induction of mesodermal cells by day 4 
was diminished in cells carrying BMPR2 mutations,, but whether their efficiency of 
differentiation into ECs is affected by these mutations remains in question. It can be 
concluded from this project, that we develop an in vitro differentiation model that 
replicates the developmental pathways of mesodermal and EC derivation in embryos, and 
suggests that BMP4 is necessary and sufficient to derive mesodermal subsets with EC 
competence but is dispensable for subsequent endothelial lineage specification.  
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1 CHAPTER I. INTRODUCTION 
1.1 Significance 
Endothelial cells are highly differentiated cells that are involved in several physiological 
processes such as angiogenesis, vasculogenesis, inflammation, coagulation and 
anticoagulation, vascular permeability, vascular tone and blood pressure. They are part of 
almost every human organ, therefore generating blood vessels and its basic unit, ECs, is a 
crucial and key step in any effort to regenerate any organ. Disturbance in the function of 
ECs have been linked to several human fatal diseases such as pulmonary arterial 
hypertension (PAH). Therefore our goal in this project was to develop an in vitro model 
to derive endothelial cells that we can use for future regenerative or disease models. 
We chose to derive these endothelial cells from human induced pluripotent stem cells 
(iPSCs). By being induced from human adult somatic cells, hiPSCs cells do not only 
overcome the ethical concerns associated with the isolation of human embryonic stem 
cells (ESCs), but they also offer an unlimited source from any patient of pluripotent stem 
cells that can differentiate to all cell derivatives of the three embryonic germ layers 
(mesoderm, endoderm and ectoderm). As hiPSCs are patient specific, they offer the 
possibility of being used as 1) autologous graft, overcoming the hurdle of allogeneic 
rejection 2) disease models, or 3) models for drug discovery. Also as hiPSCs resemble 
human late epiblast cells of post-implantation embryos, these cells offer an in vitro model 
to study development and generate cells of different lineages using directed 
differentiation protocols as proven by several studies. 
To derive ECs from hiPSCs, we chose a directed differentiation approach aiming to 
replicate those steps that are involved in the derivation of ECs during embryogenesis and 
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development. By adopting this approach we are hoping not only to increase the efficiency 
of EC derivation but also to study factors that are involved in induction and specification 
of their progenitors. In addition, using a developmental approach to derive ECs, ensures 
that their phenotype is freshly patterned without the confounding effects of disease or 
environmental exposures that is thought to alter the epigomes and phenotypes of ECs 
throughout life. The de novo derivation of ECs from iPSCs ensures epigenetic marks and 
EC phenotypes are specified anew through the simulation of embryonic development in 
vitro. Hence, in case we want to develop organ or site specific ECs, it is important to 
derive them in a developmental approach in order to preserve those initial epigenetic 
patterns. 
To develop this in vitro differentiation model, we will first review the embryonic 
development of ECs, the involved factors and signaling pathways, hiPSCs and previous 
efforts of deriving ECs from hiPSCs. We will also review the disorder, heritable 
pulmonary arterial hypertension (HPAH), since iPSC-derived ECs can be used as tool to 
possibly understand the pathogenesis of this disease. 
1.2 Embryonic development of mesoderm and endothelial cells 
To differentiate hiPSCs into ECs, it is important to review the embryonic stages and 
factors that are involved in the derivation of ECs. 
1.2.1 Early embryonic development and gastrulation 
Fertilization of oocytes marks the beginning of embryo development, where the zygote is 
formed and will undergo a series of mitotic divisions to give rise to a mass of 16 cells 
called the morula. After a series of further cell divisions and as the morula enters the 
uterine cavity, a fluid-filled cavity forms called the blastocele, and at this stage the 
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embryo is called a blastocyst. The outer layer of the blastocyst, trophectoderm, gives rise 
to portions of the yolk sac and placenta. The inner cells of the blastocyst are called the 
inner cell mass (ICM) and will form the entire fetus as well as the extra-embryonic 
mesoderm. The ICM undergoes rapid proliferation and differentiation to form the 
epiblast. A transient structure called the primitive streak (PS) will be formed in the 
posterior epiblast and its formation will mark the onset of a process called gastrulation in 
which the three embryonic germ layers will be established. With time, the PS extends 
anteriorly (disto-anterior) and will end at approximately mid epiblast in location called 
the primitive node (1,2). 
During gastrulation, epiblast cells undergo an epithelial to mesenchymal transition 
(EMT), lose E-cadherin, mobilize and move through the PS and exit either as mesoderm 
or definitive endoderm (2). Based on several molecular and lineage tracing and mapping 
studies, the anterior-posterior regions of the PS were found to have different gene 
expression patterns and developmental potential. Posterior primitive streak cells express 
HoxB1 and Evx1 and the epiblast cells that traverse through it will give rise to extra-
embryonic and lateral plate mesoderm. Cells that migrate through the more anterior 
region of posterior PS will give rise to intermediate mesoderm and paraxial mesoderm. 
Anterior PS expresses Foxa2 and the epiblast cells that traverse through it will give rise to 
definitive endoderm. This anterior-posterior patterning of the PS strongly suggests that it 
is tightly controlled by different signals and factors secreted from cells in the different 
regions of PS or in close proximity to it (1-4). 
Among several signaling pathways that are involved in gastrulation and PS formation, 
members of the TGFb family (BMP and Nodal), Wnt family and their antagonists were 
found to be essential in this anterior-posterior patterning of PS and its subsequent lineage 
specification. Nodal and Wnt3 are expressed at the posterior epiblast and found to induce 
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PS formation starting from that location (5-7). Whereas Wnt inhibitor; DKK1 and Nodal 
inhibitor; Cerberus-like and Lefty1 were found to be expressed in anterior visceral 
endoderm (anterior epiblast) (8-11). This regional expression of Nodal, Wnt3, and their 
antagonist establishes a gradient of Nodal and Wnt3 expression along the anterior-
posterior axis of the embryo and is found to be essential for anterior patterning of epiblast 
and to restrict PS formation to the posterior epiblast. At late PS stage, Nodal expression 
become restricted to the primitive node, the most disto-anterior region of PS with very 
low concentrations at the posterior region of embryo. BMP4 is secreted from extra-
embryonic ectoderm adjacent to the proximal end of the epiblast, while its inhibitors; 
Chordin and Noggin is expressed at the distal end of the epiblast (12-15). Such pattern of 
Nodal and BMP expression established a reversed Nodal and BMP4 gradient along the 
disto-proximal axis of the embryo. The results of several studies indicate that this 
reversed Nodal and BMP4 gradient is important in inducing mesodermal lineages and 
endoderm along the anterior-posterior axis of PS and suggest that high level of BMP4 and 
Nodal are required for inducing mesoderm and endoderm respectively (1-4). 
1.2.2 Mesoderm development, specification and derivation of endothelial cells. 
As mentioned previously, cells that traverse through PS will exit either as mesoderm or 
endoderm. Mesoderm cells are specified along the mediolateral axis into paraxial, 
intermediate and lateral plate mesoderm. This specification was found to be dependent on 
the concentration of BMP4, in which lateral plate mesoderm expresses higher levels of 
BMP4 than paraxial mesoderm and at the same time, paraxial mesoderm was found to 
express the BMP4 antagonist Noggin (16,17). It has been suggested that BMP4 is 
specifying the mesodermal layer by inducing differential expression of Forkhead (FOX) 
family of transcription factor, in which FOXF1 is expressed in lateral plate mesoderm, 
while FOXC1 and FOXC2 are expressed in paraxial mesoderm (18,19). 
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Paraxial mesoderm will produce somites on either side of the neural tube, which in turn 
produce muscular and skeletal elements of vertebrate. The anterior-most paraxial 
mesoderm along with neural crest will form the connective tissue, muscular and skeletal 
elements of face and skull. The intermediate mesoderm will generate the kidneys, gonads 
and the cortical portions of the adrenal gland (1). 
Lateral plate mesoderm will split horizontally into two layers, the dorsal (somatic or 
parietal) and ventral (splanchnic or visceral) layers. The splanchnic layer together with 
the endoderm will form the wall of gut tube and the cardiovascular lineages, while 
somatic layer along with ectoderm will form folds that will generate dermis of the skin, 
skeletal and muscular elements of the limbs. It will also form the extra embryonic 
mesoderm (1). 
The development of endothelial cells and blood vessels starts with the commitment of 
progenitor cells and their migration from posterior primitive streak into the extra-
embryonic yolk sac and into the embryo proper to form the extra embryonic and intra-
embryonic vascular network. The receptor tyrosine kinase Flk-1 is considered to be one 
of the markers for these progenitor cells based on findings of several studies. Dumont et 
al found that Flk1 at the primitive streak stage is expressed in the extra embryonic, 
paraxial and lateral plate mesoderm (20). Ema et al confirmed Flk1 expression using 
Flk1-lacZ knock-in model (21). Shalaby et al found that mice deficient in Flk1 display 
defect in blood island, blood vessels and endocardium and die around E9.5 (22). Lee et al 
demonstrated that in Er71 (member of Ets transcription factors and inducer of Flk1+ 
mesoderm) deficient mice were able to gastrulate, but lacked the expression of Flk1 and 
died around E9.5 due their inability to develop blood, vessels, and endocardium, similar 
to Shalaby et al findings (23). Differentiation and Fate mapping studies demonstrated that 
Flk1+ mesoderm cells contributed to hematopoietic, endothelial, skeletal and smooth 
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muscle cells (24-28). Huber et al used transgenic mice with green fluorescence protein 
(GFP) targeted to brachyury locus and showed that Flk1+ cells, before migrating to the 
yolk sac, co-express Brachyury (T) and present in highest frequency in the posterior 
primitive streak. When they isolated streak cells and cultured them in vitro, they found 
that endothelial cells were derived only from the T+Flk1+ cells, confirming the finding of 
previous studies, that Flk1+ is a reliable early marker for mesodermal progenitors of 
endothelial cells (29). VEGF is one of the ligands of Flk1, and is found to be expressed in 
endoderm juxtaposed to Flk-1 expressing mesoderm at E7.0. This complementary 
expression profile of VEGF and Flk-1 continues throughout development and can be seen 
later on in organs that are being vascularized by the angiogenesis process (20,30,31). 
Carmeliet et al used a VEGF deficient mouse model and found that these mice died due to 
abnormal blood vessel formation, similar to previous reports using a Flk-1 deficient 
mouse model (32). These findings indicate the importance of VEGF/Flk1 in mesoderm 
specification and that it is indispensable for the derivation of endothelial cells and 
vascular system development. Another important signaling pathway for mesoderm 
specification and derivation of endothelial cells is FGF signaling. It has been challenging 
to study the role of FGF signaling in the derivation of endothelial cells and 
vascularization as disturbing the gene encoding FGFR1/2 results in embryonic death 
before gastrulation (33,34). Lee et al were able to solve this challenge with the use of 
adenovirus-mediated expression of dominant-negative FGFR-1 in mouse embryos. They 
found that FGFR-1 is required for the development and maintenance of the vasculature in 
the embryo (35). 
To have a better understanding of the further specification of mesodermal progenitor cells 
into endothelial cells, it is important to address the much debated question of whether 
hematopoietic and endothelial cells share the same bipotent mesodermal progenitor, 
 7 
referred to as the hemangioblast.  Sabin et al first observed undifferentiated mesoderm 
cells migrated into the area vasculosa of the chick yolk sac and then differentiated into 
highly proliferative cells that form a solid cell mass. The outer cellular layer of this mass 
differentiated into endothelial cells while the blood plasma appeared to derive via 
liquefaction of the central core during vessel lumen formation. Furthermore, primitive 
erythroblasts appeared to directly bud from vascular endothelial cells. The differentiation 
of these two cell types, endothelium and erythrocytes, from similar undifferentiated 
mesodermal cells and the budding of primitive erythroblasts from endothelial cells lead to 
the assumption that endothelial and hematopoietic cells arise from the same progenitor 
cell, and Sabin et al initially called this cell an “angioblast" (36). In the 1930s, Murray re-
branded Sabin's "angioblast" as a "hemangioblast," to emphasize the two cell types 
deriving from this putative common progenitor (37). Circumstantial evidence provided in 
support of this common progenitor is the observation that the progenitors for endothelial 
and hematopoietic cells share common markers such as Flk1, Scl, lmo2, Tie1, Tie2, 
CD31, CD34 (22,38-42). Huber et al were able to isolate progenitor cells that co-express 
brachyury and Flk1 from primitive streak, and these cells were able to give rise to cells of 
hematopeitic, endothelial and smooth muscle lineages after in vitro culture (29). 
Supporting Huber et al’s findings, Vogeli et al in single cell fate mapping study using 
zebrafish embryos, showed that at least a proportion of the cells appeared to give rise to 
both hematopoietic and endothelial cells (43). However, arguments against the existence 
of a bona fide hemagioblast came from several studies which showed that endothelial and 
hematopoietic lineages do not appear to arise from a primitive streak-derived bipotential 
common precursor, but rather are derived from independent epiblast populations (44-46). 
Also, regarding the point that the progenitor of both lineages share similar makers can be 
challenged by the fact that knockout or knockdown experiments to study markers that can 
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delineate these lineages are not possible yet as all tested markers so far caused 
disturbance both in blood and vascular system, so they showed that these markers are 
important for both lineages, but did not for fact show that there single progenitor for both 
lineages actually express these markers (45). Another challenge to the findings of Huber 
et al (29), is criticism that the work is based solely on in vitro cultures as these 
investigators did not test the fate of these progenitors in vivo and did not provide lineage 
tracing developmental models. Hence, Huber et al had defined Bry+Flk1+ cells as 
hemangioblasts, based on in vitro potential but not fate. More recent studies now suggest 
that a common progenitor for the earliest definitive hematopoietic cells may be 
endothelial cells in specific vascular beds within the developing embryo, now referred to 
as  “hemogenic endothelium”. These cells were first observed in experiments where 
blood cells were found to be generated from a subset of phenotypically differentiated 
endothelial cells on the wall of the embryonic aorta in a region referred to as the aorta-
gonad-mesonephros (AGM.) (42,47). The concept of hemogenic endothelium was 
supported by Sugiyama et al, who used Ac-LDL-DiI to label endothelial cells at E10, and 
found that Dil positive erythrocytes were generated, indicating that they were potentially 
endothelial cell-derived (48). A middle ground to the hemangioblast vs. hemogenic 
endothelium debate was proposed by Lancrin et al, wherein the mesodermally-derived 
hemangioblast gives rise to an endothelial intermediate (hemogenic endothelium) that 
then gives rise to hematopoietic cells (49). They found that the transcription factor Scl is 
indispensable for the establishment of hemogenic endothelium, while the core binding 
factor Runx1 is critical for the generation of a definitive hematopoietic cell. The role of 
Runx1 is further supported by Chen et al (50). 
From previous sections, we reviewed the developmental stages that are involved in the 
derivation of endothelial cells, starting from the formation of PS, to lateral plate 
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mesoderm and specification to endothelial progenitor cells. We also reviewed the 
important factors that are involved as well such as members of TGFb (BMP and Nodal), 
WNT family, VEGF and FGF. In the coming sections we will discuss the embryonic and 
induced pluripotent stem cells, and their differentiation into endothelial cells lineages. 
1.3 Embryonic stem cells, induced pluripotent stem cells and differentiation 
1.3.1 Embryonic stem cells 
In 1981 Evans and Kaufman et al was the first to report the isolation and culture of 
pluripotent stem cells from mouse embryos at the blastocyst stage. The isolated cells had 
normal karyotype, expanded and maintained in an undifferentiated state, made embryoid 
bodies in vitro and formed teratomas in vivo. They termed these cells as EK (51). In the 
same year Gail R. Martin described a different method of stem cell isolation and culture, 
in which they used medium conditioned by teratocarcinoma stem cells to maintain the 
isolated pluripotent stem cells. Beside the characteristics that were described by Evans et 
al, the isolated pluripotent stem cells expressed the pluripotent marker SSEA-1. Martin et 
al was the first to refer to these cells as embryonic stem cells (EC cells) (52). 
Thomson et al isolated the first human ES cells (hESCs) from an in vitro fertilized egg in 
1998. The isolated cells had normal karyotype, express high levels of telomerase 
(indication of high replicative potential), express pluripotent markers (SSEA-3, SSEA-4, 
TRA-1-60, TRA-1-81 and alkaline phosphatase) and formed teratomas after injection into 
SCID mice. These teratomas contained derivatives of all three germ layers and in vitro 
the isolated ES cells differentiated into endoderm and trophoblast (53). 
The ability of ES cells 1) to indefinitely symmetrically self-renew while maintaining 
normal karyotype and 2) to differentiate in vivo and in vitro to cells of all three germ 
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layers, made them a valuable tool to study developmental biology, for drug discovery and 
to be a potentially unlimited source of functional human cells for regeneration and tissue 
engineering. The main obstacles preventing research progress in their clinical application 
have been the ethical controversy related to their isolation from human embryos and the 
possibility of allogeneic rejection of cells derived from ES cells if they were to be 
transplanted into patients. 
1.3.2 Induced pluripotent stem cells and reprogramming 
Shinya Yamanaka hypothesized that factors which maintain the identity of ES cells, are 
also able to induce pluripotency of somatic cells. His hypothesis emerged from three 
scientific discoveries in stem cells, developmental biology and genetic engineering fields. 
The first is somatic cell nuclear transfer to accomplish reprogramming by transferring the 
nucleus of adult differentiated cells into enucleated oocytes or by fusing differentiated 
cells with ES cells (54,55). Both methods revealed that the nucleus of even differentiated 
cells contains all the genetic information required for the development of entire organism 
and that the oocytes or ES cells contain factors that are able to reprogram somatic cell 
nuclei. Second is the discovery of master transcription factors that can induce the fate of 
different lineages (56,57). Third is the isolation of ES from mouse and human blastocytes 
(51-53). Yamanaka and his student Kazutishu Takahashi were able to induce pluripotent 
stem cells from mouse embryonic and adult fibroblasts by retroviral transduction of four 
transcription factors (Oct3/4, Soc2, c-Myc, and Klf4) under ES cell culture conditions. 
They called the isolated cells; induced pluripotent stem cells (iPSCs). The isolated iPSCs 
express pluripotent markers and had similar morphological and growth properties to ES 
cells. In addition, iPSCs formed teratomas that contain tissues from all three germ layers 
upon their transplantation in nude mice. Finally when iPSCs were injected into mice 
blastocysts, they contributed to mouse embryonic development (58). One year later the 
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same group along with Thomson et al were able to generate iPSCs from human somatic 
cells (59,60). The generation of iPSCs not only represents a solution to the ethical 
controversies and allogeneic rejection hurdles associated with ES cells but can also open 
the door for disease modeling and genetic correction of patient specific lines. 
The ability to induce pluripotent stem cells from human somatic cells is considered a 
paradigm shift in the field of stem cells, developmental biology, genetic engineering and 
tissue regeneration. In addition, since these cells resemble human late epiblast cells of 
post-implantation embryos, these cells offer an in vitro model to study development and 
generate cells of different lineages using directed differentiation protocols as proven by 
several studies (3,4). 
Despite the great potential of iPSCs, there are several issues that still need to be resolved 
to allow them to reach their full potential. First, unlike mouse iPSCs that are considered 
to be naive cells, hiPSCs, are seen as primed cells that might be biased toward specific 
differentiation potential. Second, the reprogramming process might result in incomplete 
or partially reprogrammed iPSCs, which can affect the pluripotency of the cells and result 
in defective differentiation. Third, are the challenges related to the reprogramming 
technique itself. The original re-programming technique used retroviral transduction of 
Oct3/4, Soc2, c-Myc, and Klf4 to induce pluripotency, such a technique has low iPSCs 
derivation efficiency (0.02%) and the integration of the viral vector in the host genome 
poses several risks, such as disturbing or activating neighboring genes. In addition, any 
potential reactivation of the reprogramming factors especially cMyc might be oncogenic 
(61,62). These challenges potentially limit the use of iPSCs in clinical and transplantation 
therapies. To overcome these challenges, several studies have offered techniques to 
increase reprogramming efficiency and to minimize or avoid integration into the host 
genome. 
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Sommer et al, designed a single lentiviral stem cell cassette vector (STEMCCA) encoding 
the reprogramming factors (Oct4, Sox2, Klf4 with or without c-Myc) and flanked by loxP 
sites. With the use of STEMCCA the authors reported derivation of iPSCs with 0.5% 
efficiency (63). A humanized version of STEMCCA was constructed later with similar 
efficiency (64). With such design, STEMCCA addressed two issues, first avoiding the use 
of multiple single viral vectors to deliver the reprogramming factors, resulting in higher 
efficiency than what previously reported. Second the ability to produce transgene free 
iPSCs, by using a Cre/loxP system to excise STEMCCA makes the generated iPSCs more 
suitable for clinical therapies and transplantation (63-65). 
Other integration free methods for reprogramming have been introduced. Adenovirus is 
considered to be an option, as it is a non-integrating virus, however the reported 
efficiency was very low (0.0001-0.001% and 0.0002% in mouse human cells 
respectively) in comparison to other methods (66,67). Sendai virus has been successfully 
used to reprogram blood and neonatal and adult fibroblast cells with an efficiency of 0.1-
1% in approximately 25 days. Beside the relatively high efficiency, Sendai virus is an 
RNA based virus which replicates in the form of negative-sense single stranded RNA in 
the cytoplasm of infected cells and does not go through a DNA phase nor integrate into 
the hose genome. It dilutes out of cells approximately 10 passages after infection which is 
considered an advantage and disadvantage at the same time (68,69). Warren et al were 
able to generate iPSCs from human fibroblast with an efficiency of 1.4% using mRNA 
transfection and this efficiency increases to 4.4% when they added Lin28 to the 4 
reprogramming factors and valporic acid in the cell culture medium (70). Other 
reprogramming methods were used as well such as PiggyBac vector (71), Minicircle 
vectors (72) and Episomal plasmids (73). 
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1.4 Derivation of Endothelial Cells (ECs) from hiPSCs 
ECs are highly differentiated cells that perform multiple important functions such as 
angiogenesis, vasculigenesis, and the regulation of inflammation, coagulation and 
anticoagulation, vascular permeability, vascular tone and blood pressure. Many 
laboratories are developing protocols to derive ECs from hiPSCs. In the coming sections 
we will quickly review the assays and markers that are used to identify endothelial cells, 
then will review several differentiation protocols of hESCs and hiPSCs into endothelial 
cells. 
1.4.1 Endothelial cells characterization assays and markers 
There is no single distinct marker of ECs, instead a combination of markers are used for 
EC identification. The most commonly tested endothelial markers are PECAM (CD31), 
vascular endothelial (VE)-cadherin (CD144), endothelial nitric oxide synthase (eNOS), 
von Willebrand Factor (vWF), vascular endothelial growth factor receptor-2 (VEGFR-2, 
FLK1, KDR), and Tie-2. A number of functional assays were used to characterize the 
phenotypes of ECs, such as the release of nitric oxide by ECs that can be measured in 
vitro (74). The uptake of acetylated low-density lipoprotein is another characteristic of 
healthy ECs (75). Another assay is monitoring the upregulation of adhesion molecules 
including ICAM-1 in respond to inflammatory cytokines, such as TNF-alpha (76). In 
vitro angiogenic and vasculogenic assays that require EC proliferation and migration are 
conducted by seeding ECs onto growth-factor reduced Matrigel and observing tube-like 
networks that contain lumens. Such assays were also conducted in vivo by suspending 
cells into a Matrigel plug which was then subcutaneously injected into an immune-
deficient animal. The Matrigel plug can later be removed and functional blood vessels can 
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be identified by the expression of endothelial species-specific markers in cells lining new 
blood vessels and presence of blood cells within the formed vessels (77,78). 
1.4.2 Derivation of endothelial cells from hiPSCs 
Over the last decade there was significant progress in the differentiation of hPSCs to ECs, 
with many studies using different differentiation protocols. These protocols can be 
grouped into 1) protocols using three dimensional embryoid bodies in a suspension 
culture, 2) differentiation by co-culturing hiPSCs with type of stromal cell to promote 
endothelial cell differentiation and 3) differentiating hiPSCs in monolayer (two dimension 
culture) on culture plates coated with protein substrates (Matrigel, gelatin or fibronectin). 
EB based differentiation protocols evolved from allowing spontaneously differentiating 
hESCs and hiPSCs EB to protocols that used FBS as the main differentiation factor to 
protocols that are serum free and depend on exogenous factors added with specific 
concentrations and exposure times. Levenberg et al. differentiated hESC-derived EBs, by 
withdrawing lymphocyte inhibitory factor (LIF) and bFGF and by day 13 they showed 
that 2% of cells expressed CD31. Upon isolation using flow cytometry, the isolated cells 
express other endothelial markers (CD144 and vWF) and were able to form tube like 
structure in vivo containing mouse blood cells (79). Yu et al, went one step further, they 
used two steps protocol, in which they differentiated hESC-EBs by using a 20% fetal 
bovine serum (FBS) based media for 4 days. Then the differentiated EBs were cultured 
for an additional 8 days in endothelial cell growth medium-2 (EGM-2) which contains 
2% FBS, 0.04% hydrocortisone, 0.1% heparin, 0.1% human epidermal growth factor 
(hEGF), 0.1% long R3-human insulin-like growth factor (IGF-1), 0.1% ascorbic acid, 
0.4% human fibroblast growth factor (hFGF)-B, 0.1% vascular endothelial growth factor 
(VEGF), 0.05% gentamicin, and 0.05% amphotericin-B. They reported that their 
differentiation protocol consistently yielded >10% cells that express CD31 and upon 
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isolation, more than 90% of the isolated population expressed CD31 and CD144 (80). 
Rufaihah et al used a similar approach, but they added BMP4 and VEGF in a 20% FBS 
containing media for the first 4 days, and then they withdraw BMP4 for next 10 days. 
They reported 5-20% of cells expressing CD31 by the end of the protocol. They also 
reported that the isolated CD31 cells co-express CD144 and vWF and were able to 
promote the formation of capillary like structure in vivo that contain mouse blood cells, 
although it was unclear whether the injected cells actually integrated as ECs in the new 
vessels vs provided paracrine secreted factors to promote the growth/survival of 
endogenous mouse ECs (77). James et al. used a serum free differentiation media that 
contains BMP4, Activin and FGF2 and VEGF. These conditions generated relatively 
sparse population of ECs as indicated by a VE-Cadherin-GFP reporter (0.2%). However, 
inhibition of TGFβ at day 7 increased endothelial differentiation efficiency by 10-fold. 
Subsequent TGFβ inhibition of magnetic activated cell sorting (MACS)-purified CD31+ 
cells increased their expansion 36-fold (81). White et al, used hESCs and hiPSCs to 
derive endothelial cells. First they generated KDR+ cells using a media that contained 
BMP4, Activin A and bFGF and by day 4 they reported that 55% of the cells express 
KDR. At day 4 they plated EB on fibronectin coated plate and differeniated them using 
bFGF and VEGF. By day 6 they sorted KDRhigh and found that more than 90% of the 
cells express CD31 and CD144. The sorted cells express vWF, formed tube-like structure 
in vitro and functional blood vessels in vivo (82). These studies indicate that manipulation 
of specific signaling pathways following the initial differentiation to EC progenitors 
increases cell proliferation and conservation of the EC phenotype, approaches which 
could prove vital in the derivation of tissue-specific ECs. Pure populations of ECs can be 
readily obtained using EB differentiation protocols because of the ease of sorting and 
expanding cells expressing EC markers. 
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Co-culturing of pluripotent stem cell with stromal cells is another way to derive 
endothelial cells. Vodyanik et al, cultured hESCs on OP9 for 9 days using an alpha-MEM 
based medium that contains 10% FBS. By day 9, they sorted CD34+CD43-KDR+ cells 
and plated them on gelatin with endothelial maintenance media. The plated cells, 
expressed CD31, CD144, and formed tube like structures in in vitro Matrigel assays (83). 
Choi et al used the same strategy, but they sorted CD34+CD43-CD31+ cells at the end of 
the differentiation protocol (84). 
Monolayer-based differentiation protocols using growth factors, and extracellular matrix 
have also been used to derive endothelial cells from pluripotent stem cells. Wang et al, 
developed a monolayer differentiation protocol, based on the hypothesis that EB will 
trigger spontaneous differentiation of cells intro different cell lineages decreasing the 
efficiency of specific lineages such as endothelial cells. They used a differentiation media 
that contain 20% KSR, 50ng/ml of bFGF, BMP5 and VEGF. After 10 days they isolated 
CD34+ cells and plated them in gelatin coated plates in EGM-2 media. The isolated cells 
expressed endothelial markers (CD31, CD144), and formed functional blood vessels in 
vivo (85). Tatsumi et al differentiated hESCs in the presence of a glycogen synthase 
kinase-3β inhibitor and VEGF and found that about 20% of the population expressed 
CD144 and CD31. Upon MACS purification, the sorted cells were positive for diI-
acetylated low-density lipoprotein uptake and formed capillary-like structures in vitro 
(75). Sahara et al. screened more than 60 bioactive molecules at different time points and 
developed a multi-step differentiation protocol, in which they treated the hESC and 
hiPSCs in the first 4 days with BMP4 and CP21R7 (GSK-3B inhibitor) to induce KDR+ 
cells, then for additional 2-3 days they used combination of VEGF, γ-secretase inhibitor 
DAPT (NOTCH signaling inhibitor), placental growth factor (PLGF) and hepatocyte 
growth factor (HGF) to generate endothelial progenitors (EP) cells that express CD31, 
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CD144, KDR and CD34 and finally they used VEGF for additional 7 days to generate 
mature endothelial cells. They compared EB and monolayer based differentiation 
protocols and found monolayer to be efficient. With this multi-step approach, they 
reported generation of approximately 20 million endothelial cells (EC) from 1 million 
hiPSCs. When they transplanted the hiPSCs derived EP, EC and control (HUVEC), in 
SCID mice, they reported that EP formed significantly more functional blood vessels than 
EC and HUVEC and these vessels lasted more than 3 months in the host without tumor 
formation. The authors conclude that the hESC/hiPSC-derived EP are more readily 
produced and display superior vessel forming ability compared to more mature EC and 
may be an attractive cell population for revascularization strategies in human subjects 
(86). Prasain et al. developed a protocol that relies on the use of BMP4, FGF2, VEGF and 
Activin (first 24hr) and the use of Neuropilin-1 (NRP-1) to identify a subset of EC co-
expressing CD31 and CD144 that display functional properties similar to umbilical cord 
blood endothelial colony forming cells (CB-ECFC) with high clonal proliferative 
potential and robust in vivo vessel-forming ability. The ESC-NRP-1+CD31+ ECFC and 
iPSC-NRP-1+CD31+ ECFC maintained a stable endothelial phenotype and function and 
did not undergo replicative senescence for 18 passages in vitro. Given the high rate of 
proliferation, the iPSC:EC ratio was identified as 1:1 × 108. These hiPSC derived ECFC 
engrafted and formed functional human vessels in immunodeficient mice for > 6 months. 
Furthermore, they rescued the avascular regions and blunted the neovascularization 
observed in vehicle treated mice that had undergone oxygen-induced retinopathy 
induction. The authors concluded that this unique population of iPSC-NRP-1+CD31+ 
ECFC can provide clinically relevant numbers of highly functional EC that may be a 
useful cell therapy to employ in patients that display vascular dysfunction (78). 
 18 
1.5 Heritable pulmonary arterial hypertension and BMPR2 mutation 
Pulmonary arterial hypertension (PAH) is a disease of the pulmonary vasculature that is 
pathologically characterized by progressive neointimal proliferation leading to 
vasoocclusive lesions (87). It is also characterized by muscularization at the alveolar duct 
and wall level. Such muscularization is characterized by increased smooth muscle cells 
(SMCs) proliferation, which is believed to be stimulated by dysfunctional ECs, that either 
release factors that stimulate SMC proliferation, such as FGF-2 (88), or fail to produce 
agents that normally suppress proliferation of SMCs in response to growth factors, such 
as apelin (89). PA ECs from patients with IPAH produce decreased amounts of nitric 
oxide (NO) which is a vasodilator and suppressor of SMC proliferation (90). Several 
studies found that muscularization of SMCs, is not only caused by increase in SMCs 
proliferation, but also by migration and differentiation (transformation) of resident stem 
cells (91), fibrocytes (92), pericyte or even PA-ECs into SMCs (93,94). Later in disease, 
dysregulated EC proliferation lead to the development of plexiform lesions. These lesions 
may reflect clonal expansion of apoptosis-resistant ECs, or they may be derived from 
circulating endothelial progenitor cells (EPCs) that accumulate at sites of endothelial 
denudation or injury and expand locally (95,96). Clinically it is characterized by 
progressive dyspnea, exercise intolerance, increasing pulmonary vascular resistance, and 
ultimately right ventricular failure and death (97). Under the current classification system, 
WHO Group 1 PAH is divided into heritable (HPAH), idiopathic (IPAH), and PAH 
associated (APAH) with a variety of other systemic diseases or drug/toxin exposures (98). 
No therapies tested to date have shown any significant ability to cure or reverse the 
disease and untreated PAH results in death from right heart failure in less than 3 years for 
most patients (99). 
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1.5.1 Heritable Pulpmonary Arterial hypertension 
In 1954, Dresdale et al described the familial transmission of PAH in a kindred, thus 
providing the first known reports of familial PAH, the heritable form of PAH. After 
almost 30 years, two independent teams of investigators mapped the locus for the gene, 
named PPH1, for HPAH to chromosome 2q31-32 (100,101). Subsequently, both teams 
also demonstrated that germline mutations in the gene encoding bone morphogenetic 
protein receptor type-2 (BMPR2), a transforming growth factor-β (TGF-β) superfamily of 
receptors member, was the gene responsible for the majority of cases of the autosomal 
dominant familial disease now known as HPAH (102,103). Investigators at Vanderbilt 
university identified a family which originally had 6 deaths related to PAH, they called 
this family, "family14" (as there was 13 previous families with HPAH). This family has 
mutation in the ligand-binding domain of BMPR2 (Scheme 1). Vanderbilt investigators 
followed this family and by 2011 they diagnosed 36 members with HPAH (29 females 
and 7 males) and at least another 48 members who were unaffected but who were obligate 
carriers of the mutation (104). The inheritance pattern in HPAH is best described as 
autosomal dominant with reduced penetrance which varies from 20%-80% (105,106). 
This reduced penetrance indicates that the mutation is the not the sole factor for 
developing PAH, and strongly suggests the presence of modifying genetic or 
environmental factors, which could increase or decrease the risk of developing PAH. 
 
 
 
 20 
 
Scheme 1: Schematic on BMPR2 Family 14 Mutation 
Top panel shows chromosome 2 with the location of BMPR2 gene. Middle panel shows 
BMPR2 gene which is composed of 13 exons and 4 domains. The lower panel with the 
box shows information on BMPR2 mutation 
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1.5.2 BMP signaling and BMPR2 
BMPs are the largest group of cytokines within the TGF-β superfamily and were 
originally identified as molecules regulating growth and differentiation of bone and 
cartilage (107). BMPs are involved in regulating growth, differentiation, and apoptosis of 
several cell types, and are crucial signals in embryogenesis. They also contribute to the 
homeostasis and repair of adult tissues (107-109). TGF-β superfamily type II receptors 
are constitutively active serine- threonine kinases and form homodimers that exist 
constitutively or are recruited to receptor complexes upon ligand stimulation (110). The 
BMPR2 gene is comprised of 13 exons that encode for 4 major functional domains of the 
receptor; the extracellular ligand binding domain (exons 2-3), the transmembrane domain 
(exon 4), the serine/threonine kinase domain (exons 5-11), and a long cytoplasmic tail 
(exons 12-13) that is unique amongst the TGF-β receptor family members for its length 
(Scheme 1) (102,111). BMPR-II initiates intracellular signaling in response to specific 
ligands: BMP-2, BMP-4, BMP-6, BMP-7, growth and differentiation factor-5 (GDF-5), 
and GDF-6 (111). The majority of ligands (BMP-2, BMP-4, BMP-7, and GDF-5 and 
GDF-6) bind with high affinity to the type I receptors, predominantly BMPRIA activin-
like receptor kinase-3 (ALK-3) or BMPRIB (ALK-6), and with very low affinity to 
BMPR-II. GDF-5 demonstrates specificity for BMPRIB (112). In contrast, BMP6 binds 
with high affinity to BMPR-II. After ligand binding, the type II receptor phosphorylates 
and activates a glycine-serine rich domain on the proximal intracellular portion of an 
associated type I receptor. In turn, the activated type I receptors phosphorylate 
cytoplasmic signaling proteins known as Smads (113). BMPs signal via Smads 1, 5, and 
8, which must complex with the common partner Smad (co-Smad), Smad-4, to 
translocate to the nucleus and regulate the transcription of target genes (Scheme 2) (113). 
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Scheme 2: Schematic representation of Bone Morphogenetic Proteins and Signaling 
Bone morphogenetic protein receptors 1 and 2 (BMPR1 and BMPR2) are adjacent on cell 
membranes. Bone morphogenetic protein binds to the extracellular domain (ligand 
binding) of BMPR2, resulting in the formation of a heteromeric complex with BMPR1. 
BMPR2 then phosphorylates the transmembrane region of BMPR1, activating the kinase 
domain. The activated BMPR1 phosphorylates receptor Smad (R-Smad), thus activating 
one or more receptor-dependent cytoplasmic Smad proteins (Smad1, Smad5, and Smad8), 
which bind with Smad4 and migrate to the nucleus. The phosphorylated Smad complex 
attaches to a binding factor in the nucleus, and the resulting assembly either stimulates or 
represses gene transcription by interacting with DNA.  
Newman	  J	  et	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1.5.3 BMPR2 mutation and its impact on BMP signaling and HPAH 
Several mutations were identified in BMPR2 coding regions including frame shift, 
missense, and nonsense mutations (102,103). While the majority of mutations affecting 
BMPR2 coding regions are frameshift, and nonsense mutation, about 30% are missense 
(114,115). These mutations are also affecting all BMPR2 domains, with increase risk of 
developing PAH related to mutations affecting kinase domain (116). 
Morrell et al suggested that most of BMPR2 mutations disrupt BMP/Smad signaling by 
either affecting the trafficking of BMPR2 protein to the cells surface or the 
phosphorylation of type 1 receptor that in turn affects the downstream Smad signaling 
and transcription of target genes (117,118). Reduced trafficking of the mutant BMPR2 
protein was found to be associated with missense mutations of cysteine residues within 
the ligand binding or kinase domain (118). Two explanations of such effect were 
suggested and both were linked to the retention of the mutant BMPR2 protein in the 
endoplasmic reticulum (ER). The first explanation state that the mutation leads to an 
unpaired sulfhydryl group, which could interact with other components of the ER 
chaperone, thereby preventing efficient trafficking of the protein. The second is that the 
unpaired cysteine causes interaction with the associated type I receptor, leading to failure 
of trafficking of both receptors. The later explanation was supported by Sobolewski et al, 
who reported that cysteine-substituted BMPR-II mutants retained within the ER 
prevented normal trafficking of BMPR1 receptor, but not wild-type BMPR-II (119). On 
the other hand, noncysteine mutations within the kinase domain reach the cell surface but 
fail to activate Smad-responsive luciferase reporter genes due to an inability to 
phosphorylate BMP type I receptors. Interestingly, BMPR-II mutants with missense 
mutations involving the cytoplasmic tail are able to traffic to the cell surface and are 
capable of activating Smad-responsive luciferase reporter genes to some extent but are 
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almost certainly relatively deficient in their ability to transduce signals via Smads 
(120,121). 
Several mechanisms have been proposed to explain the effect of BMPR2 in developing 
PAH. Reduced BMP signaling due to BMPR2 mutation will cause imbalance between the 
TGFb and BMP signaling which is crucial for homeostasis and maintenance of lung 
vasculature. BMP4 was found to promote endothelial proliferation, migration and tubular 
formation (122). The opposite is true, in which knockdown of BMRP2 was found to 
increase the susceptibility of pulmonary artery endothelial cells (PAECs) to apoptosis 
(123). The response of pulmonary artery smooth muscle cells (PASMCs) is in contrast to 
PAECs, in which BMP signaling has inhibitory effects on PASMC proliferation, while 
TGFb promotes their proliferation (124). Such contrasting effects of BMP signaling on 
PAEC and PASMCs could explain the initial vascular damage and the later remodeling 
noticed in PAH. It has been suggested that BMPR2 mutations may compromise the 
integrity of pulmonary endothelial barriers by promoting endothelial cell apoptosis. In 
response to exposure of increased levels of TGFb (from ingress of serum factors through 
compromised endothelial barrier and those that are released from apoptotic endothelial 
cells (125)), and reduced level of BMP signaling due to BMPR2 mutation, PASMCs will 
proliferate at higher rates, which lead to muscularization of pulmonary vasculature, 
increasing vascular resistant and pulmonary hypertension. Also it has been proposed that 
increased apoptosis in the endothelium will favor the development of apoptosis-resistant 
clones of endothelial cells and lead to plexiform lesion formation (117). 
Another mechanism by which BMPR2 mutations can contribute to PAH, is their effect on 
inflammation, as one key component in the pathogenesis of PAH is an increased level of 
inflammation manifested by elevated levels of inflammatory cytokines and infiltration of 
inflammatory cells. It has been found that the inhibition of inflammatory cytokines 
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(specifically NF-kB) is reduced in BMPR2 deficient cells, while increased TGF-B1 in the 
same cells, is related to the induction of interleukin (IL)-6 and IL-8 expression through 
inappropriately altered NF-kB signaling (126,127). Also loss of BMPR2 in the 
endothelial layer of the pulmonary vasculature could promote leukocyte extravasation 
into the pulmonary artery wall. This is supported by the findings that BMPR2 regulates 
the expression of CXCR2, which in turn regulates leukocyte migration and extravasation 
on endothelial cells (128). This was manifested in an in vitro study, in which Burton et al 
found that the enhanced transmigration of leukocytes observed in BMPR-II-deficient 
endothelium after tumor necrosis factor α or transforming growth factor β1 stimulation 
was CXCR2 dependent (129). 
1.6 Hypothesis 
After reviewing the embryonic development of ECs, the involved factors and signaling 
pathways, hiPSCs, previous efforts of deriving ECs from hiPSCs and HPAH, we 
formulated the following hypothesis: 
1- Vascular endothelial cells can be generated in vitro from human pluripotent stem cells 
via the recapitulation of embryonic developmental milestones, beginning with the 
induction of primitive streak and mesoderm followed by specification into endothelium. 
2- The resulting endothelial cells generated with this novel in vitro model can facilitate 
basic studies of human vascular development and can provide insights into the 
pathogenesis of vasculopathies such as heritable pulmonary arterial hypertension. 
In the following chapter we will review the material and methods that we developed to 
test these hypotheses. 
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2 CHAPTER II. MATERIALS AND METHODS 
2.1 Mouse embryonic fibroblast isolation, expansion and inactivation. 
Mouse embryonic fibroblasts (MEFs) were obtained from our Center for Regenerative 
Medicine (CReM) stem cell bank. These cells were previously isolated from 13.5 day old 
mouse fetuses of timed-pregnant female mice that were purchased from Charles River 
Laboratories (BALB/c, strain code: 028). MEFs were thawed in MEF culture medium, 
consisted of Dulbecco's Modified Eagle Medium (DMEM) (Gibco)/10% heat-inactivated 
Fetal Bovine Serum (FBS) (Gibco)/1% Pen/Strep/1X L-glutamine (Gibco) and plated in 
100cm2 culture dish. After expansion MEFs were inactivated via Mitomycin C (Fisher) 
treatment (10ug/ml for 2hrs) and were either frozen in 90% FBS/10% Dimethyl Sulfoxide 
(DMSO) (Sigma-Aldrich) freezing media or plated on gelatin-coated wells and used as 
feeder layers for iPSC culture. 
2.2 Human skin fibroblast expansion and reprogramming 
All human studies were approved by the institutional review board of Boston University 
and Vanderbilt University. Human dermal fibroblasts from patients with HPAH were 
obtained from Vanderbilt University. Four cells lines were received as detailed in table 1. 
To reprogram human dermal fibroblast, we used hSTEMCCA-loxP lentiviral vector, 
encoding the 4 human factors, OCT4, KLF4, SOX2 and cMYC that was previously 
described by Somers et al (64). A total of 1X105 human fibroblasts were plated in DMEM 
with 10% FBS on a gelatin-coated 6-well plastic tissue culture plate. The next day 
polybrene was added to the media (5 ug/ml), and the cells were infected with 
hSTEMCCA-loxP lentiviruses at a multiplicity of infection (MOI) = 0.1, 1, or 10. On day 
2, the media was changed to serum- free hiPSC media consisting of DMEM F12 (Gibco), 
20% KnockOut Serum Replacement (Gibco), 1 mM nonanimal L -glutamine (Invitrogen), 
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0.1 mM b-mercaptoethanol (Invitrogen), 1% nonessential amino acid solution 
(Invitrogen), and 10 ng/ml of FGF2 (Invitrogen). On day 6 the entire well was trypsinized 
and passed at a 1:16 split by plating onto gelatin-coated 6 well tissue culture plate which 
had been preseeded the day before with mitomycin C-inactivated MEFs. hiPSC colonies 
were mechanically isolated 30-35 days postinfection based on morphology and expanded 
on MEF feeders in iPSC media. Candidate iPSC clones were screened by Southern blot to 
identify those carrying only one single integrated copy of hSTEMCCA, then they were 
characterized based on immunostaining with antibodies against stage-specific embryonic 
antigen 4 (SSEA-4), TRA1- 60, and TRA1-81 (ES Cell Characterization Kit, Millipore). 
Primary antibodies were detected with secondary Alexa Fluor 488 and 568 conjugated, 
goat anti-mouse IgG or IgM (Invitrogen). 
To excise the hSTEMCCA vector, we used the method of Somers et al (64), in which 
hiPSC clones generated with hSTEMCCA-loxP lentivirus were transfected with a 
plasmid vector expressing Cre-recombinase and the Puro resistance gene. Briefly, hiPSCs 
were plated at different densities (1:20,1:40,1:60) in a 6-well plate (on MEFs) and 
cultured for 5 days with hiPSCs medium. Cells were transfected with Cre-excision 
transfection reagents; containing TransIT-HeLaMONSTER™ Transfection Kit (Mirus) 
and pHAGE2-EF1a-Cre-IRES-Puro-W plasmid. After 24 hours of transfection, cells were 
treated with hiPSCs containing 1ug/ml of Puromycin for 2 days, after that, the medium 
was changed to hiPSCs without Puromycin. After 13-15 days, surviving colonies were 
manually picked and replated into a 12-well plate and were expanded. gDNA of those 
colonies was extracted for PCR screening of hSTEMCCA excision. 
 28 
 
Table 1: List of HPAH cell lines 
  Vanderbilt ID CReM Name Phenotype HPAH Status Gender  
 1 Family 150 HAPH1 Mutation in BMPR2’s exon 12 (2504delC) Affected with HPAH Female  
 2 Family 14 HPAH2 Mutation in BMPR2’ exon 3 (354T>G) Carrier Male  
 3 Family 14 HPAH3 Mutation in BMPR2' exon 3 (354T>G) Affected with HPAH Male  
 4 Family 14 HPAH4 Mutation in BMPR2' exon 3 (354T>G) Affected with HPAH Female  
 
2.3 Tissue culture of hiPSCs 
HPAH iPSCs and normal control hiPSCs lines derived from individuals without any 
known vascular disease, specifically, BU1 (hiPSC clone BU1Cr-1), CF (hiPSC clone 
RC2 4-10-11) and 100-3 (hiPSC clone RC2 100-3), were all generated from dermal 
fibroblasts using the hSTEMCCA reprogramming system (64). These hiPSCs line were 
obtained from the CReM iPS cell bank 
(http://www.bu.edu/dbin/stemcells/index_iPSC.php). Undifferentiated hiPSCs were 
maintained and expanded on mitomycin C- inactivated MEFs, in hiPSC media. Cultures 
dishes and plates were coated with sterile gelatin (Millipore) before use. Cells were 
incubated at 37 C at 5% CO2. Approximately, every 5-7 days, cells were passaged using 
Collagenase IV (Invitrogen) and split into 1:6 ratio. 
Undifferentiated hiPSCs were also adapted to feeder-free, serum-free conditions, in 
which, cells were maintained on Matrigel (Corning) coated 6-well plates in TeSR-E8 
medium (StemCells technologies) in a 37 C incubator and 5% CO2. Approximately, 
every 5-7 days, cells were passaged using Gentle-Cell Disassociation Buffer (StemCells 
technologies) and split into 1:10 ratio. 
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2.4 Directed differentiation of hiPSCs into endothelial cells 
On Day -2, sufficient volumes of TeSR-E8, DMEM/F12, and Gentle Cell Dissociation 
Reagent for passaging were pre-warmed. The well to be passed was washed with 1 mL of 
Ca2+/Mg2+-free phosphate-buffered saline (PBS). Wash buffer were aspirated and 1 mL 
of Gentle Cell Dissociation Reagent was added and the plate was incubated at 37°C for 8-
10 min. Then cells were disloged by pipetting up and down 1-3 times using a pipette with 
a p1000 tip. Immediately the cells were transferred to a tube containing an equal volume 
of DMEM/F12. The well was washed again with 1 mL of DMEM/F12 to collect any 
remaining cells. The cells were centrifuged at 300 x g for 5 min. Then cells were re-
suspended in 1 mL of single-cell passaging medium (TeSR-E8 supplemented with 10uM 
Y27632 Rock inhibitor (Sigma)) and numbers of live cells were counted using a 
hematocytometer. Cells were plated at desired density onto Matrigel-coated plates. 
(100,000 cells per 1 well of 6-well plate. This number was optimized for the BU1 hiPS 
cell line). Different cell lines needed different seeding densities. Cells were Incubated at 
37°C and 5% CO2 for 48 hours. 
On day 0, differentiation was induced by replacing TeSR-E8 media with BFV-A 
differentiation media (media consisting of: Stemline-II base media (Sigma), BMP-4, 
FGF2, VEGF165 and Activin A (10ng/ml)(R&D)). At day 1 media was changed to BFV 
differentiation media (same as BFV-A, but without Activin A). Cells were fed every 2 
days until day 12. On Day 4, cells were passaged and replated at a seeding density of 
100,000 cells per 1 well of 6-well plate. By day10-12, cells were sorted as indicated in the 
text results, based on the expressing of endothelial markers; PECAM-1 (CD31), VE-
cadherin (CD144) and VEGF receptor-2 (KDR). Staining for these markers was 
performed using the following antibodies: 1) Fluorescein Isothiocyanate (FITC) 
conjugated monoclonal mouse anti-human CD31 (BD bioscience, Cat no. 560984), 2) 
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Phycoerythrin (PE) monoclonal mouse anti-human CD309 (KDR) (BD bioscience Cat 
no. 560494 3) Alexa Fluor 647 monoclonal mouse anti-human CD144 (BD bioscience 
Cat no. 561567). Sorted cells were plated in matrigel-coated 12 well plates at a density of 
2400 cells per well in EGM-2 media mixed 1:1 with EGM-2 containing BFV. Twelve 
days post sort, cells were passaged, replated (at a seeding density of 1x104 cells/cm2) and 
maintained in EGM-2 media. 
2.5 Flow cytometry and fluorescence activated cell sorting (FACS)  
Differentiating hiPSCs and endothelial cells were dissociated using TryplE 1X 
(ThermoFisher Scientific), washed with 2% PBS/2% FBS and stained for 30min on ice 
with monoclonal antibodies: Allophycocyanin (APC)-conjugated anti-human VE-
cadherin (CD144), Phycoerythrin (PE)-conjugated anti-human VEGF receptor-2 (KDR), 
Fluorescein Isothiocyanate (FITC) anti-human PECAM-1 (CD31) (BD-Bioscience) and 
APC conjugated anti-human Neuropilin-1 (NRP-1)(Miltenyi Biotech). After cell staining, 
cells were washed with 1ml PBS/2% FBS, spun down at 300g/5min/4°C and cell pellets 
were either resuspended in PBS/2% FBS if analyzed or in PBS/2% FBS/1 X Pen/Strep if 
sorted. Cells were either analyzed using a FACSCalibur cytometer (BD Biosciences) or 
sorted using FACSAria III Cell Sorter (BD Biosciences). Data were analyzed using 
FlowJo software (Tree Star Inc). 
2.6 Quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) 
Total Ribonucleic Acid (RNA) extraction was performed using miRNeasy Mini Kit 
(Qiagen) and 1ug DNAse-treated RNA was reverse transcribed using TaqMan Reverse 
Transcription Reagents (Applied Biosystems). qPCR of complementary deoxyribonucleic 
acid (cDNAs) was performed in a StepOnePlus real-time PCR system (Applied 
Biosystems) using TaqMan probes (table 2). Reactions were performed in triplicate. 
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Messenger RNA (mRNA) expression levels were normalized to 18S ribosomal RNA 
(rRNA) and quantification of relative gene expression presented as fold change compared 
to the relevant baseline was calculated using the 2-{delta}(delta}CT method. Biological 
triplicates from repeat experiments were used to calculate average fold change as well as 
the standard error of the mean (SEM) for each fold change in gene expression, 
represented by error bars where indicated. 
Table 2: TaqMan inventoried primers 
 Cat # Description  
 Hs00230962_m1 FOXF1  
 Hs01057416_m1 PAX2  
 Hs00365539_m1 TBX6  
 Hs00610080_m1 T  
 Hs00911700_m1 KDR  
 Hs01065282_m1 PECAM1 (CD31)  
 Hs00170966_m1 VE-Cadherin  
 Hs00204814_m1 FoxA2  
 
2.7 Immunostaining 
Cells were fixed with 4% (w/v) paraformaldehyde for 30 min and permeabilized with 
0.1% (v/v) Triton X-100 in PBS for 5 min. After blocking with 10% (v/v) goat serum for 
30 min, cells were incubated with primary following antibodies; anti-CD31 (R&D), anti-
CD144 (R&D), anti-NRP-1 (Santa Cruz) overnight at 4 °C. Cells were washed with PBS, 
then incubated with secondary antibodies conjugated with Alexa-488 or Alexa-565 
(Molecular Probe) and visualized by inverted and confocal microscopy after 
counterstaining with 2 g/ml DAPI (Sigma-Aldrich). The confocal images were obtained 
with an Olympus FV1000 mpE confocal microscope using as an Olympus uplanSApo 
60xW/1.2NA/eus objective. All the images were taken as Z-stacks with individual 10-µm 
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thick sections at room temperature and images were analyzed using FV10-ASW 3.0 
Viewer. 
2.8 Acetylated low density lipoprotein (AC-LDL) uptake 
Endothelial-like cells were incubated with 10 µg/mL DiI-Ac-LDL Alexa Fluor® 594 
Conjugate (ThermoFisher) in complete EGM-2 media for 2 hours at 37°C. Then cells 
were examined for uptake of Dil-Ac-LDL using an inverted microscopy system at 10× 
magnification. 
2.9 In vitro matrigel assay 
Endothelial-like cells were disassociated and resuspended in EGM-2 media. Cells were 
plated at a density of 1.0×104 cells per well in triplicate in 96-well plates coated with 
50µL of growth factor-reduced Matrigel (BD Biosciences). Plates were incubated 
overnight at 37°C. After 8-16 hours of incubation, photomicrographs were taken from 
each well at×10 magnification. Images were acquired using a SPOT RT color camera 
(Diagnostic Instruments) with the manufacturer's software. Phase contrast images were 
taken with air objectives. Images were analyzed using “Angiogenesis Analyzer” plug-in 
for ImageJ (Gilles Carpentier Research, http://image.bio.methods.free.fr/) to provide an 
automated quantitative assessment of network formation for the tested cell lines. The 
software quantified branches (elements delimited by a junction and one extremity), 
segments (elements delimited by two junctions), connecting segments (elements 
delimited by two junctions, none exclusively implicated with one branch) and meshes 
(area enclosed by segments or connecting segments) (130). 
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2.10 Correcting BMPR2 mutations using CRISPR/Cas 9 technology 
Mutational analysis of the gene encoding BMPR2 in six affected members revealed that 
all have a T354G missense mutation in exon 3 that encodes an amino acid substitution of 
tryptophan for cysteine. Family 14 fibroblasts that we reprogrammed into hiPSCs, have 
T354G missense mutation in exon 3 of BMPR2 gene. This mutation resulted in amino 
acid substitution of tryptophan for cysteine. Correction was done using CRISPR/Cas9 
technology, and Cas9 was delivered to iPSCs  using plasmid transfection of pSpCas9(BB) 
(Addgene #62988) (131) engineered to over-express the Cas9 enzyme together with a 
gRNA targeting the BMPR2 3rd intron. Targeting plasmids were prepared as follows. 
First a guide RNA (gRNA) was designed using the Zhang lab design tool at 
http://crispr.mit.edu. The gRNA that was selected had the following sequence: 
5’AAGGTTGAAGCCAGGCGTGA3’, designed to bind to the intron region downstream 
to exon3 of BMPR2 locus. To clone the gRNA delivery plasmid, oligos encoding the 
gRNA were ordered from IDT. The donor vector was constructed to contain homology 
arms (HA) flanking the mutation site in the BMPR2 locus but containing the BMPR2 
corrected sequence followed by a PGK promoter-driven floxed transgene encoding drug 
resistance selection cassette (Puromycin) and followed by polyA sequence. The left-HA 
was 830 bp long and 831 bp for the right-HA.  The floxed antibiotic resistance cassette 
was designed to be in the intronic sequence adjacent to the mutant exon to be corrected. 
 
Cloning of the Cas9 and gRNA delivery plasmid proceeded as follows: upon receipt of 
oligos, they were re-suspended to a final concentration of 100 uM. The top and bottom 
strand oligos were phosphorylated and annealed under the following conditions: 
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Then the annealed, phosphorylated oligos were diluted 1:200 into ddH2O, and stored at -
20 °C. The pSpCas9(BB) plasmid (Addgene #62988) was digested with BbsI enzyme 
under the following conditions: 
 
 
 
The digested product was run on 1% (wt/vol) agarose gel to visualize digested vector. 
Then gel extract and product purification was stored at -20 °C. The digested vector 
backbone (BB) and annealed, phosphorylated oligo insert (gRNA) was then ligated 
together under the following conditions: 
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Constructing the Cas9/gRNA plasmid 
 
17. Choose a pSpCas9(BB) vector best suited for the experiment and order from 
Addgene (http://www.addgene.org/).  We typically use a single plasmid 
containing both Cas9 and gRNA:  pX459 (Puro), pX458 EGFP) or pX330. 
 
18. Upon receipt of oligos, resuspend them to a final concentration of 100 uM.  
Phosphorylate and anneal the top and bottom strand guide oligos under the 
following conditions: 
 
Amount (uL) Component 
1 gRNA top strand, 100 uM 
1 gRNA bottom strand, 100 uM 
1 T4 PNK 
1 T4 Ligation Buffer, 10X 
6 ddH2O 
10 Total 
 
19. Dilute the annealed, phosphorylated oligos 1:200 into ddH2O, can store at -20 
°C. 
 
20. Digest the pSpCas9(BB) plasmid with BbsI enzyme under the following 
conditions:  
 
 
 
 
 
 
 
 
 
 
 
 
 
21. Run digested product on 1% (wt/vol) agarose gel to visualize digested vector.  
Gel extract and purify product, can store at -20 °C. 
 
22. Set up a ligation reaction of the digested vector and annealed, phosphorylated 
oligos under the following conditions (also set up a negative control, vector 
only): 
Temperature Time 
37 °C 30 min 
95 °C 5 min 
Ramp to 25 °C 5 °C/min 
Amount (uL) Component 
x pSpCas9(BB), 1 ug 
1 BbsI 
5 Buffer 2.1 
1 CIP 
to 50 ddH2O 
50 Total 
Temperature Time 
37 °C 2 hr 
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Following ligation, we treated the reaction with PlasmidSafe Exonuclease to remove any 
residual liner DNA under the following conditions: 
  
 
 
Transformation of chemically competent Stbl3 E. coli was performed using the heat 
shock method. Two uL of plasmid was added to 20 uL cells, mixed and incubated on ice 
for 30 minutes. Heat shock was performed at 42 °C for 30 seconds and E.coli were 
immediately returned to ice for 2 minutes. Then we added 600 uL SOC medium to the 
mix and incubated at 37 °C (shaking) for 1 hour. Then cells were pelleted at 4000 rpm for 
2 minutes to remove all but 100 uL of media, followed by resuspension and plating onto 
LB+ampicillin (100 ug/mL) plates overnight at 37 °C. Inspection for colony growth was 
performed the next day. We inoculated several colonies into LB + ampicillin (100 ug/mL) 
and grew them at 37 °C (shaking) overnight. Before harvesting for DNA extraction, we 
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23. Following ligation, treat the reaction with PlasmidSafe Exonuclease to remove 
any residual linear DNA under the following conditions: 
 
Amount (uL) Componen  
11 Ligation Reaction 
1.5 PlasmidSafe Buffer, 10X 
1.5 10 mM ATP 
1 PlasmidSafe Exonuclease 
15 Total 
 
NOTE: PlasmidSafe Reaction can be stored at -20 °C for up to 1 week or directly 
transformed. 
 
24. Transform into the chemically competent Stbl3 E. coli strain. Add 2 uL product 
to 20 uL cells, mix gently by flicking the tube and incubate on ice for 30 
minutes.  Heat shock at 42 °C for 30 seconds and immediately return to ice for 2 
minutes.  Add 600 uL SOC medium to mix, incubate at 37 °C (shaking) for 1 
hour.  Pellet cells at 4000 rpm for 2 minutes, remove all but 100 uL media, 
resuspend and plate all onto LB+ampicillin (100 ug/mL) plates.  Incubate 
overnight at 37 °C. 
 
25. Inspect for colony growth the next day.  There should be no colonies on the 
negative control plate and many colonies on the pSpCas9(BB) plates. 
 
26. Inoculate several colonies into LB + ampicillin (100 ug/mL) and grow at 37 °C 
(shaking) overnight. 
 
27. Before harvesting for DNA extraction, streak cultures onto LB+ampicillin (100 
ug/mL) grid plate to retain correct clones (saves time in avoiding 
retransformation of miniprepped plasmid). Incubate this plate overnight at 37 
°C. Store at 4 °C. 
Amount (uL) Component 
2 T4 Ligation Buffer, 10X 
1 T4 DNA Ligase 
0.5 pSpCas9(BB) vector 
3 gRNA 
13.5 ddH2O 
20 Total 
Temperature Time 
16 °C Overnight 
Temperature Time 
37 °C 30 min 
70 °C 30 min 
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negative control plate and many colonies on the pSpCas9(BB) plates. 
 
26. Inoculate several colonies into LB + ampicillin (100 ug/mL) and grow at 37 °C 
(shaking) overnight. 
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streaked cultures onto an LB+ampicillin (100 ug/mL) grid plate to retain correct clones. 
Then we prepared miniprep of the plasmid DNA according to the QIAprep spin miniprep 
kit instructions. After sequence verification, maxiprep was prepared using Qiagen 
EndoFree Maxiprep Kit. 
 
To transfect the Cas9-gRNA encoding plasmid by nucleofection, we pre-treated hiPSCs 
in iPS media containing 10 uM Y-27632 (ROCK inhibitor) for 3 hours before 
transfection. Then cells were dissociated using Accutase for 5-7 minutes to attain a single 
cell suspension. Cells were passed through a 30 um strainer to remove cell clumps. Cells 
were spun at 200 x g for 4 minutes. Then cuvettes were prepared with cells and plasmid 
DNA mixture (2 ug Cas9/gRNA, 3 ug donor plasmid).  After spinning and aspiration of 
supernatant, we added 100 ul P3 Solution+Supplement (Lonza) per cuvette to the cell 
pellet. Next using the Amaxa Nucleofector, we transfected the cells using CB-150 
program. Then cells were incubated overnight at 37 °C, 5% CO2/5%O2 to allow cells to 
attach. Twenty-four hours later, media was replaced with fresh media without Y-27632. 
Then colonies were picked after being challenged with Puromocyn. Surviving colonies 
were picked into 12-well plates, expanded and PCR screening of gDNA was performed to 
identify successfully targeted clones. After choosing colonies that were potentially 
successfully targeted with the corrected BMPR2 template, we Cre-excised the intronic, 
floxed Puromycin resistance cassette, by transient transfection of plasmid Cre-IRES-
NeoR as described before in making hiPSCs section. Successful targeting, BMPR2 
mutation correction, and excision of the PuroR cassette was confirmed by both PCR of 
gDNA and sequencing of the BMPR2 locus (see table 3 for primers.) 
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Table 3: Primers used for PCR to verify the correction 
	   Primers	   Sequence	   Binding	  sites	   	  	   BMPR2	  cDNA	  	  	  	  
Forward:	  	  GATCCGTATCAGCAAGACCTTGGG	  
Reverse:	  CAACTGGACGCTCATCCAAGGAGC	  
Forward:	  88,535	  ..	  88,558	  
Reverse:	  114,375	  ..	  144,398	  
	  	  	  	  	   BMPR2	  cDNA	  sequencing	   GCTCGAAAGGTAGCACCTGCTATG	   88,602	  ..	  88,625	   	  	   BMPR2	  Integrity	  of	  Target	  site	  	  	  	  
Forward:	  	  TGTTGATTTGCAAAACTGTTTCATAGC	  
Reverse:	  ACAGGCGCCTACCACTACGCCCGG	  
Forward:	  91,078	  ..	  91,104	  
Reverse:	  93,419	  ..	  93,442	  
	  	  	  	  	   BMPR2	  Family	  14	  mutation	  sequencing	  	   GATTTATAGGATGTTGGTCTCACATTG	   91,201	  ..	  91,227	   	  	   3’	  Know-­‐in	  	  	  	  	  
Forward:	  	  GCCAGAGGCCACTTGTGTAGCGCCAAG	  
Reverse:	  	  CACTGCAGTAAACAACTCAAT	  
Forward:	  93,040	  ..	  93,066	  
Reverse:	  94,136	  ..	  94,156	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3 CHAPTER III: RESULTS 
3.1 Two stages of directed differentiation of hiPSCs into mesodermal progenitors 
with endothelial cells competence. 
Prasian et al published a 12 day serum-free, feeder-free, two dimensional, monolayered 
protocol to derive endothelial colony forming cells (ECFC) from hiPSC using four 
factors, Activin-A (for 24 hours only), BMP4, FGF2 and VEGF. This protocol resulted in 
the generation of ECFC that were similar to cord blood (CB) ECFC in their endothelial 
marker expression profile, high proliferative potential, and the ability to form functional 
blood vessels in vivo (78). To test our first hypothesis, we chose this protocol as a model 
to investigate the kinetics of hiPSC differentiation and whether the cells are 
differentiating through stages that recapitulate those that are involved in embryonic 
endothelial cells development. To improve the reproducibility of the protocol, we applied 
the following changes: 1) differentiation of dispersed, adherent cells plated in 2D as 
single cell suspensions instead of colony based 2D differentiation, 2) cells were passaged 
by day 4, 3) seeding cell density at day-2 and day4 was optimized for each cell line. To 
investigate the kinetics of the differentiation protocol, we looked at protein and gene 
expression for primitive streak (T), endoderm (FOXA2), mesoderm (KDR), lateral plate 
mesoderm (FOXF1), paraxial mesoderm (TBX6), intermediate mesoderm (PAX2) and 
endothelial (KDR, CD31 and CD144) markers by FACS analysis and RT-qPCR at 
different time points. FACS analysis shows 28.8% of differentiating cells express cell 
surface marker for mesoderm; KDR, by day4 and by day12 this percentage increases to 
almost 100%. By Day12, 7% of the cells express cell surface markers for endothelial cells 
(CD31 and KDR), these cells were sorted, replated and maintained in EGM-2/BFV 
media. FACS analysis of the sorted cells at day24 (Day12 post sort) shows 92% of the 
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cells express CD31 and CD144, indicating the possibility of generating endothelial-like 
cells by that time based on expression of endothelial cells surface markers (CD31 and 
CD144) only at this stage (Figure-1 B). 
Gene expression kinetics by RT-qPCR of unsorted cells undergoing directed 
differentiation shows a transition through a primitive streak stage characterized by 
transient brachyury (T) expression that peaks by day 2 to a mesoderm stage indicated by 
expression of mesodermal markers: KDR, FOXF1, PAX2 and TBX6). Note the 
heterogeneous nature of the mesoderm produced by day 4, including the generation of 
cells expressing markers of lateral plate (FOXF1), intermediate (PAX2,) or paraxial 
mesoderm (TBX6). By day 8-12 the protocol promotes lateral plate mesodermal marker 
(FOXF1) expression at the expense of expression of intermediate mesoderm. Note also 
the transient expression of low levels of anterior primitive streak (non-mesodermal) 
marker (FOXA2) within the first 4 days of the protocol and its downregulation by day 4 
of the protocol, indicating the absence of anterior primitive streak or endodermal cell 
outgrowth in days 4-12 of this protocol (Figure-1 C). 
It can be concluded from the kinetic experiments, that BMP4, FGF2 and VEGF (with 
Activin for 24hrs), promotes the differentiation of hiPSCs through stages that recapitulate 
those involved in the embryonic derivation of endothelial cells, in which cells progress 
through a primitive streak-like state (T+) to mesoderm and subsequently to a population 
of cells 90% of which express endothelial cell surface markers (CD31, CD144 and KDR), 
indicating the possibility of generating potential endothelial-like cells. 
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Figure 1: Two stages of directed differentiation of hiPSCs into mesodermal 
progenitors with EC competence 
A. Schematic of feeder free, serum free two-stage differentiation protocol for the  directed 
differentiation of hiPSC into endothelial colony forming cells with high proliferative 
potential.  
B. Kinetics of cell surface KDR and CD31 protein expression, at indicated stages of 
differentiation. After sorting by day 12, 92% of cells express CD31 and CD144 and can 
be serially passaged. 
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C. Gene expression kinetics by RT-qPCR of unsorted cells undergoing directed 
differentiation through the 2 stage protocol, indicating progression through a primitive 
streak stage characterized by transient brachyury (T) expression that peaks by day 2 to a 
mesoderm stage indicated by expression of the mesodermal markers: KDR, FOXF1, 
PAX2 and TBX6.) Note the heterogeneous nature of the mesoderm produced by day 4, 
including the generation of cells expressing markers of lateral plate (FOXF1), 
intermediate (PAX2,) or paraxial mesoderm (TBX6). By day 8-12 the protocol promotes 
lateral plate mesodermal marker (FOXF1) expression at the expense of expression of 
intermediate mesoderm.  Note also the transient expression of low levels of anterior 
primitive streak (non-mesodermal) marker (FOXA2) within the first 4 days of the 
protocol and its downregulation by day 4 of the protocol, indicating the absence of 
anterior primitive streak or endodermal cell outgrowth in days 4-12 of this protocol.  
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3.2 Differentiation of iPSCs yields an endothelial-like population that maintains high 
proliferative potential and expression of endothelial cell surface markers over 
several passages. 
To investigate the phenotypic and functional characteristics of the generated cells and 
whether they resemble ECFC, we used several known characterization assays to test: 1) 
proliferative capacity, 2) expression of endothelial markers, 3) morphological 
characteristics, and 4) ability to form functional blood vessels in vivo. 
To assess the proliferative potential of the sorted CD31+CD144+KDR+ cells, they were 
plated at low density (600 cells/cm2) in a 12-well plate. As cells attach and form colonies, 
the cell number composing single colony  (several colonies were chosen randomly) was 
counted at different time points. Over 11 days (post-sort; total differentiation day 23), our 
results show a range of increases in cell numbers in different colonies,  ranging from 11 
to 90 fold increases over input numbers, indicating that this differentiation protocol 
yielded endothelial-like cells with variable proliferative potential (Figure 2). 
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Figure 2: sorted CD31+CD144+KDR+ cells derived from hiPSCs produce colonies 
with variable proliferative potentials 
A) Schematic indicating the post-sorting time points, in which the numbers of cells were counted 
B) Line chart showing the proliferation of two colonies of the sorted CD31+CD144+KDR+ cells 
over 11 days post sort. These results show that colony 1 had 11 fold increase in the cell number 
over 11 days, while colony 2 had a 90 fold increase. These results indicate that different colonies 
had different proliferation potentials. 
C) Microscopic images showing the increase in cell number over 11 days post sort. 
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One of the characteristics of ECFC is the expression of endothelial cell markers and their 
ability to proliferate for extended periods of time in vitro without drifting to non-
endothelial phenotypes. To assess the expression of endothelial markers after passaging 
sorted CD31+CD144+KDR+ cells, RT-qPCR and FACS were performed. The results 
show similar protein and transcript gene expression levels of endothelial markers (CD31 
and CD144) between the sorted cells and CB-ECFC (Figure-3 A, B). To confirm the 
expression of endothelial markers, we immunostained the sorted CD31+CD144+KDR+ 
cells for CD31 and NRP-1, and results show typical cobblestone morphology and protein 
expression pattern of CD31 and NRP-1 of the sorted cells as endothelial cells (Figure-3 
C). Hence our results show that the sorted cells maintained the expression of endothelial 
cell surface markers (CD31 and CD144) over 8 passages, indicating the maintenance of 
phenotype based at least on markers expression (Figure-3 B). 
Endothelial cells are characterized by being able to uptake acetylated low density 
lipoprotein (Ac-LDL). To assess the ability of sorted iPSC-derived CD31+CD144+KDR+ 
cells to show similar characteristics, they were incubated with media containing Dil-Ac-
LDL for 2 hours, and microscopic images were taken. These images reveal that sorted 
cells were positive for Ac-LDL uptake (Figure-3 D) similar to endothelial cells (data not 
shown). 
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Figure 3: The sorted CD31+CD144+KDR+ express and maintain endothelial markers 
over 8 passages 
A) RT-qPCR showing similar gene expression level of endothelial markers (CD31 and 
CD144) of the sorted CD31+CD144+KDR+ with CB-ECFC. 
B) FACS plot showing that the sorted CD31+CD144+KDR+ cells expressing and maintain 
endothelial markers over 8 passages. 
C) Immunostainning showing of the sorted CD31+CD144+KDR+ cells, showing typical 
cobblestone morphology and expression of CD31 and NRP-1 
D) AC-LDL uptake assay was positive for the sorted CD31+CD144+KDR+ cells 
 
 46 
Another characteristic of endothelial cells is their ability to form network structures in in 
vitro matrigel assays. To investigate the ability of the sorted CD31+CD144+KDR+ cells to 
form similar network structures to ECFCs, Sorted iPSC-derived putative ECs, vs CB-
ECFC and IMR-90 fibroblast positive and negative controls, respectively, were plated on 
96-well plates pre-coated with thick matrigel. After 16 hours, images were taken and 
analyzed using ImageJ software with AngioAnalyzer plug-in. Results show that both CB-
ECFC and iPS-EC formed similar number of branches, segments, connecting segments 
and meshes in comparison to the negative control; IMR-90  (Figure 4). Note that as the 
structures become more complex, CB-ECFC performed better than iPS-EC. These results 
indicate that the sorted cells were able to form network-like structure but were performed 
less than CB-ECFC, as the complexity of the structure increase. 
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Figure 4: The sorted CD31+CD144+KDR+ were able to form network like structure 
in in vitro matrigel assay, but was less complex than CB-ECFC 
A) Microscopic images (Top panel) of in vitro matrigel assay for the sorted 
CD31+CD144+KDR+ cells, CB-ECFC and IMR-90. Lower panel shows computed images 
generated with ImageJ. 
B) Bar graph showing the number of structures created by each cell type, calculated 
through automated plug-in in ImageJ.  
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In order to test the ability of iPS-EC to form functional blood vessels in vivo, cells were 
sent to our collaborators (Laboratory of Dr. Mervin C. Yoder, Indiana University) to 
prepare Matrigel plugs containing iPSC-derived EC (iPS-EC). These plugs were 
implanted subcutaneously in SCID mice. After 24 days following transplantation, the 
plugs were harvested by dissection, fixed with paraformaldehyde, and tissue sections 
were prepared for histology studies including immunostainings with anti-human CD31 
antibody (Figure 5). iPS-EC were able to survive the in vivo assay and able to form tube-
like structures that were stained with anti-human CD31 antibody. However in comparison 
to CB-ECFC, iPS-EC failed to form tube-structures that enclose circulating red blood 
cells, indicating that these tubes failed to anastomose with host vasculature and therefore 
were not able to function as vessels compared to the primary CB-ECFC controls (Figure 
5). 
It can be concluded from the several in vivo and in vitro characterization assays, that this 
directed differentiation protocol yields an endothelial like population, a subset of which 
were able to maintain high proliferative potential and expression of endothelial cell 
surface markers for at least 8 passages. Although the cells engineered from iPSCs possess 
other endothelial cell characteristics, such as the capacity to take up Ac-LDL, and form 
tube-like structures in 3D matrigel they are not functionally identical to CB-ECFC in 
vivo. 
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Figure 5: Sorted CD31+CD144+KDR+ cells derived from iPSCs were able to survive 
and make tube like structure in vivo, but failed to harbor blood cells in comparison 
to CB-ECFC controls. 
Histological sections of Matrigel plugs that were seeded with sorted CD31+CD144+KDR+ 
cells or CB-ECFC and implanted in SCID mice. The images show that the sorted 
CD31+CD144+KDR+ cells were able to form tube like structures positive for human-
specific CD31 by immunostaining, but devoid of any circulating blood cells, indicating 
that these tubes did not anastomose with the host vasculature. In contrast CB-ECFC 
sections show two types of tube like structures: those that harbor blood cells (Black arrow 
and red-box) and those that do not (Blue-box). Note blue box structures appear  similar to 
those formed by the sorted CD31+CD144+KDR+ iPS-ECs. 
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3.3 BMP4 is necessary and sufficient for the induction of endothelial competent 
mesoderm but is dispensable for subsequent lineage specification of endothelial 
like cells. 
After developing an in vitro model to differentiate hiPSCs into endothelial like cells, the 
next step for the project is to test the second hypothesis by using this model to study 
human vascular development and pathogenesis of vasculopathies such as HPAH. As 
discussed before, about 80% of HPAH is caused by a mutation in BMPR2. While 
BMPR2 mutations are present in every cell in the body and BMPR2 protein is expressed 
in a wide variety of tissues and cell types, it is unknown why only the pulmonary 
vasculature shows clinically apparent abnormalities. It is also unknown whether there is a 
developmental abnormality in lung-specific endothelial cells. Our in vitro differentiation 
model depends on BMP4, which is one of the ligands of BMPR2 used to derive ECs from 
hiPSCs, therefore it is possible to use this model to investigate the role of BMP signaling 
in the derivation of endothelial cells in vitro and to begin to develop and in vitro disease 
model. 
To study the role of BMP signaling in EC derivation from hiPSCs, we first sought to 
determine the stage dependent requirements for exogenous BMP4 in our two staged 
protocol. We designed an experiment (Scheme 3) in which BMP4 was used as the only 
differentiating factor, or was withdrawn or blocked using the BMP antagonist, Noggin, at 
the induction (Day0-4) and/or specification (Day4-12) stages of the protocol. Description 
of conditions is shown in Table 4. FACS analysis and gene expression by RT-qPCR were 
performed on day 4 and day12.  
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Scheme 3: Schematic summarizing the media abbreviations and combinations tested 
for induction and specification stages of the protocol. 
 
 
 
Table 4: Medium's components for different conditions 
 
 
 
 
 
 
 
 
 
 Name Components  
 M Base media with no factors added  
 BFV Base media with BMP4, FGF2 and VEGF  
 FV Base media with FGF2 and VEGF  
 B Base media with BMP4 only  
 FVN Base media with FGF2, VEGF and BMP inhibitor Noggin  
 Note that all conditions had Activin for the first 24 hours  
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Day4 FACS analysis shows that conditions lacking BMP4 (M, FV and FVN), result only 
in KDR+dim cells, while  while conditions that contain BMP4 (B and BFV) induce two 
distinct populations: KDR+bright and KDR- cells, similar to our results using all factors 
(BFV) (Figure 6). Day12 FACS analysis shows that CD31+CD144+ cells only arise from 
those conditions that were exposed to BMP4 at the induction stage (day0-4) and from 
those conditions that contain FGF2 and VEGF at the specification stage (day4-12). These 
FACS results indicate that BMP4 in this protocol is required for inducing mesodermal 
cells with endothelial competence, but is not required for specifying them toward 
endothelial cells lineages. However the opposite is true for FGF2 and VEGF: while they 
are not required for inducing the endothelial competent mesodermal cells, they are 
necessary for lineage specification into endothelial cells. 
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Figure 6: Stage-dependent BMP4 is necessary and sufficient for the induction of 
endothelial competent mesoderm but is dispensable for subsequent lineage 
specification of endothelial-like cells. 
Panels on the left are FACS plots of day 4 cells differentiated in the conditions indicated from day 
0-4 (all conditions include day 0-1 exposure to Activin). (M = base media with no factors added, 
B = BMP4 only, BFV = BMP4, FGF2 and VEGF, FV = FGF2 and VEGF, FVN = base media 
with FGF2, VEGF and the BMP inhibitor, Noggin). Note the 2 distinct populations of KDRhigh 
and KDR- cells are present only in those two conditions that contain BMP4. The middle panel is a 
bar graph representing the % of CD31+CD144+ cells by FACS on day12 (after day 4-12 culture 
in each indicated media cocktail). CD31+CD144+ cells arise only from those precursor cells that 
were patterned in BMP4-containg conditions (B or BFV from day0-day4.) The right panel is a 
FACS plot of day24 cells. These cells were sorted at day 12 after being induced by either B or 
BFV at the induction stage, then specified by either FV or BFV. The similar percentage of 
CD31+CD144+ cells, supports the conclusion that BMP4 is necessary and sufficient at the 
induction stage but is dispensable at the specification stage.  
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To confirm the FACS results, we performed RT-qPCR for cells exposed to BFV, FV and 
B conditions at each day during the induction stage (Day0-4) to define the kinetics of 
gene expression of primitive streak (T), endoderm (FOXA2), mesoderm (KDR), lateral 
plate mesoderm (FOXF1), paraxial mesoderm (TBX6) and intermediate mesoderm 
(PAX2). All conditions had Activin for the first 24 hours. The results show that cells 
which exposed to FV had low expression of primitive streak (T), lateral mesoderm 
(FOXF1) and intermediate mesoderm markers (PAX2) and up regulation of endoderm 
marker (FOXA2) and paraxial mesoderm marker (TBX6) over the 4 days of induction. In 
contrast, those cells which were exposed to B and BFV conditions show transient 
upregulation of primitive streak marker (T), upregualtion of lateral plate and intermediate 
mesoderm (FOXF1 and PAX2 respectively) and low expression of endoderm and 
paraxial mesoderm marker (TBX6) over 4 days of induction (Figure 7 A). The gene 
expression kinetics results show that cells proceed through primitive streak stage and 
subsequently to lateral and intermediate mesoderm stage only in those conditions that 
contain BMP4 (B and BFV). These results indicate BMP4 is required to induce the cells 
to differentiate through primitive streak stage to lateral and intermediate mesoderm while 
both exogenous FGF and VEGF is dispensable. In support of this conclusion day 4 gene 
expression level of cells exposed to the FV condition or to conditions with no exogenous 
factors (M), were similar for all tested markers (T, FOXA2, FOXF1, PAX2 and TBX6), 
indicating that at least for the tested markers, FV and VEGF had no significant 
differentiation effect during the induction stage (Figure 7 B). Similar experiments were 
done during the specification stage, in which the cells that were exposed to conditions 
that contain BMP4 (B and BFV) were exposed to BFV or FV conditions to investigate if 
BMP4 is required during the specification stage, and Day 12 RT-qPCR results show 
similar gene expression of mesoderm markers (KDR, FOXF1, PAX2 and TBX6) and 
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endothelial markers (KDR and CD31) in conditions regardless of whether BMP4 is 
present on days 4-12. This indicates that BMP4 is dispensable at the specification stage 
(Figure 7 C). 
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Figure 7: In contrast to BMP4, FGF and VEGF do not promote the differentiation 
of pluripotent stem cells through primitive streak to mesodermal stage cells. 
A) Line graph showing kinetics of gene expression (by RT-qPCR) of primitive streak (T), 
endoderm (FOXA2), mesoderm (KDR), lateral plate mesoderm (FOXF1), paraxial mesoderm 
(TBX6) and intermediate mesoderm (PAX2) markers at the induction stage and with three 
conditions (BFV, B, or FV).  
B) Bar graph showing a comparison of gene expression by hiPSCs that were exposed to FV or M 
at the induction stage.  
C) Bar graph showing a comparison of gene expression by hiPSCs that were exposed to BFV or 
FV at the specification stage, after being induced by either BFV or B conditions. 
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It can be concluded that in this in vitro differentiation model, BMP4 is necessary and 
sufficient for the induction of endothelial competent mesoderm but is dispensable for 
subsequent lineage specification of endothelial-like cells. On the other hand the opposite 
is true for FGF2 and VEGF, in which they are required for the specification of endothelial 
like cells after the induction of endothelial competent mesoderm, but they are dispensable 
at the primitive streak and mesoderm induction stages. To further validate this conclusion 
we differentiated hiPSCs in parallel using 2 protocols: 1) the original protocol that used 
BFV through all 12 days (78) and 2) Our new protocol using B in the first 4 days 
(induction stage) and FV on days 4-12. On day 12 CD31+CD144+ cells were sorted and 
replated as described before. At day 24, FACS analysis was done for the sorted cells from 
both protocols, revealing that both protocols resulted in similar percentages of 
CD31+CD144+ cells (Figure 6). 
To further understand the role of BMP4 in the derivation of the endothelial competent 
mesoderm, we exposed hiPSCs to BMP4 for different lengths of time (24hr, 48 hours, 96 
hours and 120 hours) and then switched to conditions that contain FV and VEGF only till 
day 12 (Figure 8 A). FACS analysis and RT-qPCR were done at day 4 and 12. The 
results shows that as little as 24 hours of exposure to BMP4 results in successful 
induction of primitive streak and mesoderm markers (T, FOXA2, KDR, FOXF1, TBX6, 
PAX2 and CD31) and percentages of KDR+bright mesoderm and CD31+CD144+ EC-like 
cells at days 4 and 12, respectively.. It can be concluded from this experiment that 24 
hours of BMP4 exposure is sufficient to induce endothelial competent mesodermal cells. 
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Figure 8: Twenty-four hours of BMP4 exposure is sufficient to induce endothelial 
competent mesodermal cells. 
A) Schematic summarizing the media and combinations tested at different time points. 
B) Left panel shows FACS plots of cells exposed to different durations of BMP4. Results show 
similar percentages of KDR+bright cells are induced by different BMP4 durations. Right panel 
shows bar graph of percentage of CD31+CD144+ cells on day 12 resulting from precursors 
exposed initially (days 0-4) to different durations of BMP4. 
C) Gene expression of several markers after being induced by different BMP4 exposure times. 
Results shows that as little as 24 hrs of BMP4 exposure was enough to induce the cells to proceed 
through PS stage into mesodermal cells with endothelial competence.  
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3.4 The generated hiPSCs lines from skin fibroblasts isolated from patients with 
HPAH, have normal karyotypes and their mutations in the BMPR2 gene can be 
corrected successfully with CRISPR/CAS9 technology. 
After developing an in vitro directed differentiation protocol of hiPSCs into endothelial 
like cells, and achieving a better understanding of the role of BMP signaling in deriving 
endothelial-like cells, we decided to use this model to test the following hypothesis “The 
induction of endothelial competent mesoderm is compromised in hiPSCs lines derived 
from patient with BMPR2 mutations, resulting in insufficient derivation of endothelial-
like cells”. To test this hypothesis, we planed an experiment (Scheme 4) that will consist 
of: 1) generating hiPSC lines from individuals that carry known BMPR2 mutations and 
either do or do not have clinical PAH, 2) correcting BMPR2 mutations in all iPS cell 
lines, 3) differenting all cell lines toward endothelial to assess the role of defective 
signaling.  This approach allows the generation of endothelial-like cells in a head to head 
syngeneic comparison of iPSC lines both before vs after correction of their BMPR2 
mutations by gene editing.   
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Scheme 4: Schematic of the strategy to test the effect of disturbed BMP signaling 
due to BMPR2 mutation. 
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Using the hSTEMCCA reprogramming system (Figure 9 A), we were able to generate 
hiPSCs from dermal fibroblast that were isolated from patients with HPAH. The 
generated HPAH1, 2, 3 and 4 hiPSC lines were immunostained with antibodies specific 
for human pluripotency markers SSEA-4, TRA-1-60 and TRA-1-80. Immunostaining 
shows that all HPAH-hiPSCs lines were positive for all pluripotent markers (Figure 9 B). 
After successful reprogramming, we excised the floxed hSTEMCCA vector with transient 
expression of Cre recombinase and confirmed the excision of STEMCCA by PCR of 
gDNA (Figure 9 C). G-banding analysis of the generated HPAH hiPSCs revealed normal 
karyotypes in each gene edited/correct clone as well as their parental clones with no 
apparent chromosomal abnormalities (Figure 9 B).  
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Figure 9: The generated HPAH-hiPSCs show normal karyotype and express 
pluripotent markers. 
A) Vector schematic illustrating the polycistronic lentiviral STEMCCA backbone encoding four 
reprogramming factors. A loxP site inserted in the viral 3’ LTR is duplicated to the 5’ LTR during 
viral infection and reverse transcription. The resulting floxed vector integrated in the host 
mammalian genome can then be excised by Cre recombinase. 
B) Characterization of HPAH hiPSC clones, showing expression of typical pluripotent stem cell 
markers. Bottom panel shows normal karyotypes of generated HPAH hiPSC clones. 
C) RT-PCR showing excision of STEMCCA when compared to non-cut-control 
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Next we sought to correct the mutation using CRISPR/Cas9 technology. Sequencing data 
showed that all family 14 HPAH-hiPSCs lines were successfully corrected. (HPAH2, 3 
and 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
 
Scheme 5: Schematic of CRISPR/Cas9 correction strategy. 
The top panel shows CRISPR/Cas9 vector with the gRNA. The middle shows BMPR2 
locus with Cas9 nuclease bind to the intron region downstream of exon 13 guided by 
gRNA. The bottom panel shows the donor vector with corrected sequence of BMPR2 
within the left homology arm, loxP site (for cre-excision) and PuroR-cassette for 
selection. 
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After correcting the BMPR2 mutation in each line we performed two pilot experiments. 
First, we differentiated both HPAH1 and 100-3 iPSC lines using our in vitro 
differentiation protocol, and investigated the induction of KDR+bright cells by day 4 and 
the percentage of CD31+CD144+ cells by day 9 by FACS. We also looked at markers for 
primitive streak (T), endoderm (FOXA2) and endothelial cells (KDR, CD31 and CD144) 
by RT-qPCR. FACS results showed successful induction of KDR+bright cells in 100-3 
when compared to HPAH1 (60.5% compared to 49.8% respectively), although statistical 
analysis was not performed in this n=1 pilot study. Both hiPSCs lines generated about 
12% of CD31+CD144+ indicating that derivation of EC-like cells using our protocol may 
be feasible despite the presence of BMPR2 mutations (no statistical analysis was done) 
(figure-10 A). During the induction stage there was no apparent differences in the 
expression levels of all markers tested, with the possible exception of FOXA2 expression 
which appeared to be strong in HPAH1. By day9, there was about 10000 and 4000 folds 
change in the expression level of CD144 and CD31, respectively, in HPAH1-hiPSCs 
while about 2000 fold change in the expression level of both CD144 and CD31 in 100-3-
hiPSCs (figure-10 B). Taking in consideration the limitations (comparing two different 
hiPSC lines from two different human beings and with different genetic backgraounds) 
related to this pilot experiment, the prelimenary results raise the possibility that the 
disturbed BMP signaling due to BMPR2 mutation could affect the induction of 
endothelial competent mesodermal cells, but not their specification to endothelial like 
cells. The second pilot experiment was designed to control for limitations in the previous 
experiments. Controlling for the effects of genetic background we differentiated 
HAPAH4-hiPSCs pre vs post correction of BMPR2. We measured the percentage of 
KDR+bright cells over the 5 induction days by FACS (Figure-10 C). These preliminary 
results suggest the corrected HPAH4-hiPSCs percentage of KDR+bright cells may be higher 
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than the uncorrected HPAH4-hiPSCs at each time point measured (note that no statistical 
analysis was performed due to the lack of replicates at each time point). This result 
suggests that BMPR2 mutations might affect the induction of KDR+bright cells or 
endothelial-competent mesodermal cells. The effect on generating endothelial like cells is 
still not investigated, and the implication that dampened BMP signaling in the BMPR2 
mutant cells is responsible for this effect remains a likely possibility that requires further 
testing. 
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Figure 10: BMPR2 mutations potentially affect the induction of KDR+bright cells. 
A. FACS plots of HPAH1-hiPSCs and 100-3-hiPSCs differentiated using media 
containing Activin (24hrs), BMP4, FGF2 and VEGF for 9 days.  
B. Gene expression levels by RT-qPCR. Note expression levels of FOXA2 during the 
induction stage in HPAH1-hiPSCs when compared to 100-3-hiPSCs.  
C. Line chart represent the percentage of KDR+ cells that was induced by differentiating 
HPAH4-hiPSCs (corrected and uncorrected). Note the consistent higher percentage of 
KDR+ cells generated by HPAH4-hiPSCs corrected when compared to the uncorrected 
line. 
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4 CHAPTER IV: DISCUSSION 
We aimed in this project to develop an in vitro directed differentiation model to derive 
ECs from hiPSCs, which can be used for future regenerative therapies or disease models 
and we formulates the following hypothesis "Vascular endothelial cells can be generated 
in vitro from human pluripotent stem cells via the recapitulation of embryonic 
developmental milestones, beginning with the induction of primitive streak and 
mesoderm followed by specification into endothelium". To test this hypothesis, we 
adopted a recently published serum free, feeder free protocol (78) that used four factors 
(Acitivin (first 24 hrs), BMP4, VEFG and FGF) to derive ECs from hESCs and hiPSCs. 
The novel aspect of this published protocol, is that the authors were able to derive a 
population of ECs that resemble CB-ECFC in their high proliferative potential, functional 
vessels capabilities and maintain their phenotype in vitro for at least 18 passages without 
senescence or shifting to non-endothelial phenotypes. The authors called this population 
of ECs as iPS derived endothelial colony forming cells (iPS-ECFC). Lacking in this 
protocol was assessment of the kinetics of differentiation and assessment of whether the 
cells are going through stages that recapitulate those involved in the embryonic derivation 
of endothelial cells during in vivo development. During embryogenesis, ECs are derived 
from mesodermal cells that have been induced from posterior PS, therefore, when we 
tested the kinetics of the protocol, we were looking for markers that indicate the induction 
of primitive streak and subsequent mesodermal cells (1-4). Brachyury (T) is a pan PS 
marker, that has been used in many studies to trace the induction of PS (2-4,29,132). On 
the other hand, Flk-1 (KDR) is considered both a mesodermal and 
hematopoietic/endothelial progenitor marker (2-4, 29). Using these two markers, Huber et 
al was able to trace the induction of PS through the expression of T (using ESCs from a 
transgenic mouse with GFP targeted to brachyury locus) and subsequently the induction 
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of mesodermal cells through the expression of Flk-1. These investigators found that 
endothelial cells were derived only from the T+Flk1+ cells (29). Several other studies 
used a similar strategy to trace the derivation of endothelial cells (81,132,133). Therefore, 
we chose to look at the expression of T and KDR (Flk1) to test the kinetics of 
differentiation and to confirm the induction of PS and its transition into mesoderm. As 
mesoderm cells exit the PS, they are specified along the mediolateral axis into paraxial, 
intermediate and lateral plate mesoderm (1,2,19). Cells that form the cardiovascular 
system and the vasculature of all endodermal organ systems, including the lungs, are 
believed to be derived from the lateral plate mesoderm (1). Therefore, it was essential for 
us to investigate which mesodermal subsets will be induced using this differentiation 
protocol. Hence, we tested the kinetics of FOXF1 (lateral plate mesoderm), PAX2 
(intermediate mesoderm) and TBX6 (paraxial mesoderm). Besides mesoderm, PS 
(specifically anterior PS) can give rise to endoderm, thus to test whether this protocol 
promotes endoderm formation at any stage, we used FOXA2 which is an anterior PS and 
endodermal marker (2,3). Finally, to trace specification into endothelial cells, we used 
known endothelial markers; CD31 and CD144. The results of our kinetic experiments 
show that over the first 4 days of the protocol, cells proceed through primitive streak 
stage (as revealed by the transient expression of T that peaked by day 2) and subsequently 
differentiate into a population of mesodermal cells that express markers of lateral plate, 
paraxial and intermediate mesoderm. FACS analysis at day 4 shows that about 30% of 
cells are KDR+bright. With continued exposure to BMP4, VEGF and FGF for an additional 
8 days, RT-qPCR results show upregulation of lateral plate mesodermal marker FOXF1 
in comparison to paraxial and intermediate markers and FACS results shows a population 
of cells (7%) that co-expresses CD31, CD144 and KDR. When the generated 
CD31+CD144+KDR+ cells were sorted and replated in endothelial maintenance media, 
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more than 90% of cells express endothelial markers (CD31 and CD144), indicating the 
possibility of generating endothelial-like cells. The kinetics experiments, indicate that this 
in vitro differentiation protocol directed hiPSCs into PS and mesoderm stages that 
subsequently gave rise to endothelial-like cells, potentially replicating the process of 
endothelial cell derivation during development. Such transition of hiPSCs into PS and 
subsequently into KDR+ mesodermal cells during the first 4 days can be attributed to the 
induction effect of Activin and BMP4. In vivo studies indicate that Nodal and WNT 
signaling are essential in the formation of PS at the posterior epiblast. This was confirmed 
by several in vitro studies. Nostro et al found that, although BMP4 is not required for the 
induction of PS, the presence of BMP4 promoted posterior PS formation by day3. 
Evseenko et al, found that combining Activin and BMP4 with FGF2 and VEGF improved 
the induction of KDR+ mesodermal cells by day3.5 (134). Although this protocol favors 
lateral plate mesoderm over intermediate and paraxial mesoderm, which could indicate 
that the generated endothelial-like cells are lateral plate derived, this assumption need to 
be confirmed through further experiments such as lineage tracing of lateral plate 
mesodermal derivatives or by co-staining the day12 CD31+CD144+KDR+ with lateral 
plate, paraxial and intermediate mesoderm markers.  On another point, there was a 
transient upregulation of FOXA2 that peaked by day 3 and then was downregulated for 
the remaining 9 days. These results indicate that this protocol did not promote endoderm 
formation and such transient expression of FOXA2, albeit at low levels, can be explained 
by transient formation of anterior PS-like phenotype in some cells. These FOXA2 levels 
appear to be far lower than the robust levels achieved previously in our laboratory’s 
publications using dedicated endodermal (e.g liver, lung, or thyroid) protocols, although 
we have not compared these FOXA2 levels head to head in experiments in this current 
project. 
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After testing the kinetics of the protocol and generating endothelial-like cells, it was 
essential to characterize the generated cells and compare them to CB-ECFC using criteria 
described by Prasian et al (78): 1) expression and maintenance of endothelial markers 2) 
high proliferative potential and 3) capacity to generate functional blood vessels in vivo. 
The generated cells expressed endothelial markers (CD31 and CD144) and maintained 
that expression for at least 8 passages. They also expressed endothelial markers (CD31 
and CD144), were positive to Ac-LDL update assay, and were able to form network 
structures in matrigel in vitro assay, all similar to CB-ECFC. When the generated 
CD31+CD144+KDR+ cells were seeded within Matrigel plugs and transplanted 
subcutaneously in SCID mice they survived and formed tube-like structures that were 
positive for human specific anti-CD31 antibody, but failed to harbor blood cells, 
indicating that these tube-like structures did not anastomose with the host vascular 
network, and therefore may not be functional. From the kinetics and characterization 
assays, our data indicate that this in vitro differentiation model induces hiPSCs into stages 
that replicate those involved in the derivation of endothelial cells in vivo, namely 
formation of PS, followed by mesoderm, followed by ECs. It also yielded an endothelial 
like population that maintained high proliferative potential and expressed endothelial cell 
surface markers over several passages. Therefore, our data indicate that it is possible to 
use this in vitro differentiation model to investigate the factors that are involved in the 
induction of the different mesodermal subpopulations and their specification into 
endothelial cells. It can also be used to derive endothelial-like cells for regenerative 
models. One of the hurdles that needs to be solved is the inability of the generated ECs to 
form functional blood vessels in vivo. Possible explanations for this observation include 
our iPS-ECs assuming a developmental phenotype that may be more or less mature than 
CB-ECFC or contamination of our cells with fibroblastic cells either by loss of 
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endothelial phenotype or outgrowth of low levels of competing fibroblasts surviving our 
original day 12 sorts. It should be noted that mature primary ECs, in contrast to CB-
ECFC, also do not exhibit functional transplantation capacity in matrigel plugs. Hence 
our results do not necessarily negate our interpretation that many of our iPS-EC are 
endothelial-ike cells even though they may differ in some ways from primary CB-ECFC.  
It should be emphasized that the possibility of loss of endothelial phenotype in 
cultures in favor of other mesenchymal or fibroblastic phenotypes is well known. For 
example, it is known that endothelial cells can lose their phenotypic markers and acquire 
mesenchymal or myofibroblast phenotype during embryonic development, fibrotic 
disorders and when they cultured in vitro, in a process called endothelial to mesenchymal 
transition (EndoMT) (78,81,135-139). During several differentiation attempts we noticed 
a similar phenomena in which the sorted endothelial-like cells lost their expression of 
endothelial markers (CD31 and CD144) and acquired fibroblast morphology, as the 
number of passage increased, which indicates a possibility of EndoMT. Similar 
phenomena have been noticed in several published differentiation protocols. The 
molecular mechanism underlying EndoMT is not completely understood and is less 
explored compared to epithelial to mesenchymal transition. Several studies point to the 
role of TGF-Β in causing EndoMT and its inhibition lead to the maintenance of 
endothelial phenotype in some studies (81,136). James et al used such a strategy of 
inhibiting TGF-Β through the use of SB431542 during the differentiation of hiPSCs, 
which increased the generation of endothelial like cells by 10 fold. Continuing the 
inhibition of TGF-Β after sorting the endothelial like cells maintained their proliferation, 
phenotype and resulted in a net of 36-fold expansion of endothelial cells. Using an Id1-
YFP hESC reporter line, they found that the maintenance of endothelial phenotype 
through TGF-Β inhibition is mediated through the sustained expression of Id1 (81). Their 
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findings support previous studies which indicate that Id1 is required for the maintenance 
of vascular cell fate (140). We investigated the effect of inhibiting TGF-Β using 
SB431542 after sorting and replating CD31+CD144+KDR+ cells on the maintenance of 
endothelial phenotype and found no significant improvement (data not shown). But we 
did not try the effect of TGF-Β inhibition during the differentiation (specifically in the 
specification stage), which could possibly help in generating a more stable and perhaps 
more functional endothelial like population. This is a potential area for future 
investigation. Another possibile explanation for the lack of in vivo functional capability 
of our sorted CD31+CD144+KDR+ cells could be related to the difference in the sorting 
algorithm that we used in comparison to the Prasain et al protocol. At day 12 we sorted 
cells according to the co-expression of three markers; CD31, CD144 and KDR. While 
Prasain et al (78), sorted according to the co-expression of CD31 and NRP-1 (brighter 
half of NRP-1 cloud on FACS plots). According to their findings, this sort gate promoted 
the generation of more ECFC colonies and resulted in formation of functional blood 
vessels in vivo in similar numbers to those formed by the positive control (CB-ECFC). 
They reported that with the use of their sorting algorithm they were able to purify a 
population of ECFC that maintained their phenotype for 18 passages without the need to 
use TGF-Β inhibition. Interestingly, their data also revealed that even with the use of such 
sorting algorithm, about 50% of the sorting cells had low proliferative potential to non-
dividing cells (therefore not ECFC). Similar findings were noticed with CB-ECFC. Also 
both CB-ECFC and hiPSC-ECFC resulted in formation of tube-like structures that did not 
harbor blood cells and look similar to tube-like structure that were formed by our iPS 
derived endothelial like cells. This indicates that their sorted cells are still not a 
completely pure population of ECFC. In preliminary experiments, we chose not to adopt 
such a sorting algorithm as we found that KDR+ cells by day 12 completely co-express 
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NRP-1 preventing further meaningful subgating on NRP-1 stained populations. However, 
we did not sort the brighter half of KDR+ cells, an approach that we might consider to 
investigate in an effort to increase the yield of high proliferative endothelial like cells. 
Another potential reason for not forming functional blood vessels in vivo could be related 
to the use of late passage sorted cells instead of early passage cells. As mentioned 
previously, we noticed that with increased numbers of passages, some cells start losing 
their cell surface marker expression endothelial profiles and have lower proliferative 
potential. Therefore before using the generated endothelial-like cells in any regenerative 
model, we have to address the issue of in vivo functional blood vessels forming 
capabilities. 
HPAH is a disease of the pulmonary vasculature with 80% of reported cases carrying 
mutations in BMPR2 (117). While BMPR2 mutations presumably are expressed in a 
broad diversity of tissues and lineages, it is unknown why only the pulmonary vasculature 
shows clinical abnormalities. It is also unknown whether there is a developmental 
abnormality in the lung specific endothelial cells. Our in vitro differentiation model 
depends on BMP4, which is one of the ligands of BMPR2, to derive ECs from hiPSCs. 
Our data also indicate that this in vitro differentiation model potentially recapitulates the 
embryonic stages involved in the derivation of endothelial cells. Therefore it is possible to 
use this model to: 1) investigate the role of BMP signaling (and disturbed signaling due to 
mutation in BMPR2 gene) in the derivation of endothelial competent mesodermal 
progenitors and ECs in vitro, and 2) assist in studying the phenotype of endothelial cells 
generated from hiPSCs lines with mutations in BMPR2. Therefore, we first decided to 
investigate the role of BMP4 in different stages of the differentiation, and we designed an 
experiment in which BMP4 was used as the only differentiation factor during mesodermal 
induction (Day0-4) and/or endothelial lineage specification (Day4-12) stages of the 
 75 
protocol (note that Activin was used in all conditions for the first 24hrs). Our results 
indicate that exposure to as little as 24 hours of exogenous BMP4 is necessary and 
sufficient to induce mesodermal cells with endothelial competence, and once induced, 
these mesodermal cells do not require BMP4 to specify to endothelial like cells. On other 
hand although exogenous FGF2 and VEGF exposure were not required to induce the 
endothelial competent mesodermal cells, they are required to specify them into 
endothelial like cells. 
Nostro et al (133) found that Activin and WNT were sufficient and necessary for the 
induction of PS and FLK1+ mesodermal cells. While BMP4 was not required, but adding 
it promoted the derivation of posterior PS and committed mesodermal Flk1+ cells with 
endothelial competence. Our data shows that 24hr of BMP4 exposure was sufficient to 
induce the endothelial competent KDR+bright cells, while 24hr of Activin without 
exogenous source of BMP4 was not sufficient. The difference between our results and 
Nostro et al paper, can be attributed to the different species (Human vs mouse) and 
difference in differentiation setting were Nostro et al used EB based protocol, while we 
used monolayer based protocol. Evseenko et al (134) study, using hES model, found that 
significant increase in induction of KDR+bright cells was noticed only when BMP4, was 
supplemented with FGF2 and VEGF. While our data found no effect of supplementing 
BMP4 with VEGF or FGF2 on percentage of KDR+bright cells. Again the difference in the 
results could be attributed to the difference between EB based protocol (Evseenko et al 
paper) and our monolayer based protocol. To completely address whether BMP is 
absolutely required in our protocol in contrast to Nostro el al (133) we would need to 
repeat our protocol removing or blocking BMP4 in the presence of both Activin and Wnt 
stimulation. Thus it remains possible that as Nostro et al proposed BMP may be 
dispensible if downstream Wnt and TGFB/Activin signaling are stimulated during PS and 
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mesodermal induction. What is a common finding between Nostro et al (133), Evseenko 
et al (134) and our findings, is that BMP4 was not required for specifying KDR+ (Flk1+) 
cells into CD31 expressing cells, while VEGF is required. (keeping in mind that 
Evseenko et al used FBS as supplement to derive ECs from KDR+ cells). A similar 
finding was reported by Patsch et al (141) in which VEGF was not required for the 
induction of mesodermal progenitors while it is required for their specification to 
endothelial-like cells. 
Other interesting findings in our experiments include our observation that in conditions in 
which 1) no factors was added or 2) combination of FGF2 and VEGF (and with Noggin) 
were used (with 24hr of Activin) during the induction stage, this resulted in upregulation 
of FOXA2 expression compared to conditions that contained BMP4. This could indicate 
that these conditions favored anterior primitive streak, an outcome that was suppressed by 
BMP4 in our studies in keeping with prior work by Keller and colleagues (2-4,132,133). 
As we developed a better understanding of the role of BMP signaling in the derivation of 
endothelial like cells in our in vitro differentiation model, we formulated the following 
hypothesis "The induction of endothelial competent mesoderm is compromised in hiPSCs 
lines derived from patients with BMPR2 mutations resulting in insufficient derivation of 
endothelial-like cells". To test this hypothesis, we obtained fibroblast cells from patients 
having mutation in BMPR2 and affected or not with PAH. We reprogrammed the cells 
into hiPSCs and corrected the mutation using CRISPR/CAS9 technology (131,142). Then 
the corrected and uncorrected cells from the same cells line were induced for 4 days with 
combinations of Activin (first 24 hours), BMP4, VEGF and FGF. The results implied a 
lower percentage of KDR+bright cells in the uncorrected line over the 5 days induction time 
when compared to corrected line. This finding indicates a possibility of less endothelial 
competent mesodermal cells, but this assumption needs to be confirmed by statistical tests 
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on replicated results and characterizing these mesodermal cells and investigating their 
ability to generate endothelial like cells (CD31+CD144+KDR+) by the end of the protocol. 
Our other preliminary and less controlled pilot experiment, in which HAPH1-hiPSCs 
compared to 100-3 hiPSCs showed that although there was less induction of KDR+bright 
cells by day in HPAH1-hiPSCs lines, the percentage of CD31+CD144+KDR+ was similar 
in the two lines, indicating that the lower induction, may not affect the percentage of the 
endothelial like cells. Our plans to study the effect of disturbed BMP signaling due to 
BMPR2 mutation on the generation, phenotype and function of the endothelial like cells 
will continue through our collaboration with the Yoder lab at Indiana University, in which 
the in vivo functional blood vessel capabilities of endothelial like cells from HPAH-
hiPSCs lines (corrected and uncorrected) will be tested and compared.  
Through this project we were able to develop an in vitro differentiation model to derive 
endothelial like cells from hiPSCs via the recapitulation of embryonic developmental 
milestones, beginning with the induction of primitive streak and mesoderm followed by 
specification into endothelium. We were able to provide a better understanding of the role 
of BMP signaling at different stages of the differentiation, in which BMP4 was found to 
be necessary and sufficient to induce endothelial competent mesodermal cells, but was 
dispensable at the specification stages. Finally we started to use this in vitro 
differentiation model to develop a disease model of HPAH, by generating hiPSCs from 
patients with a mutation in the BMPR2 gene, correcting the mutation using CRISPR/Cas9 
technology, and finally providing preliminary results on the effect of potentially disturbed 
BMP signaling due to BMPR2 mutation on the induction of endothelial competent 
mesoderm. We believe that the differentiation model can be further enhanced by 
optimizing it to generate endothelial like cells with in vivo functional blood vessels 
forming capabilities 
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